---
title: May 2025
date: 2025-05-31
categories: [Newsletters]
tags: [ai, clinical trials, llms, data privacy, causal inference]
description: This issue explores cutting-edge applications of artificial intelligence in clinical research, covering advancements in patient selection, causal inference, secure data collaboration, synthetic data generation, Large Language Model integration for trial management, and real-time monitoring, all aimed at enhancing efficiency and patient outcomes.
---

# Introduction

Artificial intelligence (AI) is systematically transforming clinical research by addressing long-standing challenges in trial design, execution, and patient management. Recent advancements leverage sophisticated computational approaches to enhance precision, accelerate processes, and improve the reliability of findings. This compilation explores innovative applications spanning patient selection and enrollment, robust causal inference for treatment effect evaluation, secure data collaboration and the generation of synthetic data, the strategic deployment of Large Language Models (LLMs) for streamlining trial workflows, and AI-driven real-time monitoring to enable adaptive interventions. Collectively, these developments aim to optimize resource utilization, improve patient outcomes, and foster more efficient and ethical pathways for medical innovation.

# AI for Smarter Patient Selection and Trial Enrollment

Efficient patient selection and recruitment are critical bottlenecks in clinical trials, often leading to delays, increased costs, and compromised generalizability of research findings. Artificial intelligence, particularly Large Language Models (LLMs) and advanced analytical techniques, is revolutionizing this landscape by enabling more precise patient identification, phenotyping, and subgroup stratification. These advancements aim to automate eligibility assessment, optimize recruitment for specific trial designs, and leverage multimodal data for highly precise patient selection, thereby enhancing trial efficiency and the relevance of personalized treatments.

## Automating Patient-to-Trial Matching with LLMs

A significant stride in streamlining clinical trial processes is the development of AI-powered recommendation systems for patient-to-trial matching. **TrialMatchAI** [1](https://arxiv.org/pdf/2505.08508v1) presents an end-to-end system that automates this process by integrating heterogeneous clinical data, including structured records and unstructured physician notes. The system leverages fine-tuned, open-source LLMs within a Retrieval-Augmented Generation (RAG) framework, employing Chain-of-Thought (CoT) reasoning for criterion-level eligibility assessments. This approach ensures transparency by providing traceable decision rationales, which is crucial for clinical acceptance. Its modular design and lightweight deployment footprint make it suitable for clinical environments, particularly for identifying suitable trials, including complex biomarker-driven studies. In validation, TrialMatchAI demonstrated high recall and precision, with 92% of oncology patients having at least one relevant trial within the top 20 recommendations [1](https://arxiv.org/pdf/2505.08508v1).

Despite its promise, TrialMatchAI, like other LLM-based systems, is susceptible to confabulations and misclassifications, necessitating robust monitoring. A key practical limitation lies in its reliance on the Phenopackets exchange format, which requires converting patient data from native Electronic Health Record (EHR) systems (e.g., OMOP) into this standardized format [1](https://arxiv.org/pdf/2505.08508v1). This data conversion process can be a significant barrier to direct implementation in existing clinical workflows, highlighting the ongoing challenge of data harmonization in healthcare. The broader landscape of medical LLMs is actively addressing the complexities of real-world clinical text understanding [2](https://www.semanticscholar.org/paper/3982dd06568c983e94cd748ddaf123829160ee7e) and the extraction of structured information from unstructured notes [3](https://www.semanticscholar.org/paper/6d586605660e0351d9e29ce8f6c8fae1c4c271b4), [4](https://www.semanticscholar.org/paper/ecc3051e19f7713350e0950b6cde1f0841ca2d7c), which could alleviate some of these data integration challenges.

## Refining Patient Phenotypes and Subgroup Stratification

Beyond direct trial matching, LLMs are also being applied to refine patient phenotyping, enabling the identification of more homogeneous patient cohorts for improved clinical trial design. Traditional clustering methods often struggle with the high-dimensional, heterogeneous nature of healthcare data and lack contextual understanding. A novel approach demonstrates the potential of LLMs to cluster patients into subgroups based on clinical, demographic, and socioeconomic data [5](https://arxiv.org/pdf/2505.09805v1). By serializing patient records into text and embedding them using quantized LLMs (e.g., LLAMA 3.1 8B, Stella-En-400M-V5 with a clustering objective), the method generates embeddings that lead to better-defined clusters than classical techniques.

This contextual phenotyping can lead to several improvements in clinical trials: more effective targeting of specific patient subgroups, enabling personalized treatment strategies, optimizing resource allocation by focusing interventions on vulnerable populations, and designing more robust trials with refined stratification and outcome measurements [5](https://arxiv.org/pdf/2505.09805v1). While promising, the study acknowledges limitations, including its reliance on a synthetic dataset, which may not fully capture real-world data complexity. The "black-box" nature of transformer models also poses challenges for clinical transparency and acceptance, underlining the critical need for explainability in AI applications in medicine. The computational requirements of LLMs remain a practical hurdle for widespread adoption, particularly in resource-limited settings where such advancements could be most beneficial. Related research in semi-supervised representation learning frameworks like SCORE aims to characterize multi-domain disease profiles from large-scale EHR data, supporting the broader goal of identifying meaningful patient phenotypes [6](https://www.semanticscholar.org/paper/70fcc9b10b76566a93d7a02fbcc8b597c25068c4).

## Precision Treatment and Biomarker Discovery

The drive towards personalized medicine necessitates identifying patients who will most benefit from specific treatments and understanding the underlying biomarkers. Several advanced analytical techniques are emerging to address this:

Firstly, a novel methodology leverages Shapley Additive Explanations (SHAP) values in conjunction with Conditional Average Treatment Effect (CATE) modeling to identify predictive biomarkers [7](https://arxiv.org/pdf/2505.01145v1). This approach addresses the inherent challenges of applying SHAP in complex, multi-stage CATE strategies by introducing a pragmatic surrogate estimation method, which significantly reduces computational burdens. By enabling researchers to interpret complex machine learning models in the context of clinical trials, this method facilitates the identification of patient subgroups most likely to respond to specific therapies, thus optimizing trial design and patient selection. However, the computational complexity of model-agnostic SHAP approaches, especially KernelSHAP, can be prohibitive for large covariate sets. The utility of the explanations also depends on the accuracy of the underlying CATE model; explaining a poor prediction offers limited value [7](https://arxiv.org/pdf/2505.01145v1).

Secondly, the **Double-NN** method advances Individual Treatment Effect (ITE) estimation by using deep neural networks within an Extended Fiducial Inference (EFI) framework [8](https://arxiv.org/pdf/2505.01995v1). This method accurately estimates ITEs and quantifies their uncertainty, allowing for more informed, patient-specific treatment decisions. Its ability to model complex, nonlinear relationships through deep neural networks can capture intricate patient characteristics that influence treatment outcomes. The Double-NN method has shown superior performance in prediction interval coverage and length over methods like Conformal Quantile Regression (CQR), leading to more reliable treatment effect estimations that aid in clinical trial design, patient stratification, and assessing treatment effect variability. Limitations include the need for extensive testing on diverse clinical trial datasets to fully assess generalizability and robustness, as well as the considerable computational cost and hyperparameter tuning required for deep neural networks.

Thirdly, to address the complexities of optimizing treatment assignments in trials with numerous treatment options, a "calibration-weighted treatment fusion" method has been proposed [9](https://arxiv.org/pdf/2505.08092v2). This approach tackles data scarcity within specific treatment groups and unbalanced covariate distributions across treatments. By robustly balancing covariates and fusing similar treatments, it enables the application of advanced Individualized Treatment Rule (ITR) learning techniques, leading to more robust and flexible treatment recommendations. This method, grounded in theoretical guarantees of consistency and double robustness, has demonstrated practical utility in real-world patient data (e.g., Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma). A primary limitation, however, is its potential instability when applied to treatment arms with very few or no observations, highlighting a dependency on sufficient patient representation [9](https://arxiv.org/pdf/2505.08092v2). This aligns with broader challenges in dynamic treatment regimes that aim for personalized, real-time decision-making, which often struggle with optimal strategy derivation [10](https://www.semanticscholar.org/paper/b6973a9299073ba8bbea732cb2935e5924a811b2).

Finally, for more cost-effective and efficient trials, an active learning strategy called **FCCM (Factual and Counterfactual Coverage Maximization)** has been introduced to optimize patient selection for treatment effect evaluation [11](https://arxiv.org/pdf/2505.05242v1). By adaptively choosing which patients to include and label, FCCM aims to reduce the overall number of patients required while maintaining estimation accuracy. This is particularly valuable for expensive procedures like tumor imaging or biopsies. The method proposes a greedy radius reduction algorithm that efficiently identifies and labels informative samples by considering both factual and counterfactual outcomes. Its strength lies in reducing the financial and logistical burdens of clinical trials by optimizing resource utilization. However, FCCM relies on assumptions of strong ignorability and partially overlapping distributions, which may not always hold in real-world clinical data.

## Leveraging Multimodal Data for Enhanced Diagnostics and Reasoning

The integration of diverse data modalities is crucial for comprehensive patient understanding and precise clinical decision-making. AI is making significant strides in multimodal reasoning for diagnostics and patient characterization:

**MINT (Multimodal Integrated kNowledge Transfer)** offers a framework to enhance unimodal LLM performance in biomedical tasks by transferring knowledge from multimodal biomedical data (e.g., images, text) through preference optimization [12](https://arxiv.org/pdf/2505.05736v1). This is particularly promising for improving patient selection and stratification by enhancing the accuracy of rare disease prediction and tissue classification. MINT’s approach preserves general LLM capabilities while boosting domain-specific performance, potentially accelerating the development of more accurate diagnostic tools and biomarkers crucial for clinical trials. A limitation is its dependence on the quality of the upstream multimodal model and its reduced accuracy in zero-shot scenarios for diseases not in the training data, which could limit its generalizability in identifying trial-suitable patients for novel treatments [12](https://arxiv.org/pdf/2505.05736v1). This aligns with broader efforts to build robust medical multimodal LLMs (MLLMs) and address challenges like resource efficiency and clinical considerations [13](https://www.semanticscholar.org/paper/fd1d271d0cb4aba04aea8a495cfb2f85e03ac310).

In medical Visual Question Answering (VQA), **MMedAgent-RL** proposes a novel multi-agent system that simulates a clinical workflow with a triage doctor, specialists, and an attending physician [14](https://arxiv.org/pdf/2506.00555v1). By using reinforcement learning (RL) with a curriculum learning strategy, it addresses inconsistencies in specialist outputs, leading to more robust and precise diagnostic decision-making. This framework's human-like reasoning process, where it analyzes problems and decides whether to follow specialists, enhances interpretability and trustworthiness, which is vital for clinical trial adoption, potentially improving patient selection. However, its dependence on proprietary models limits transparency and reproducibility. The framework's effectiveness is primarily tested on medical VQA datasets, which may not fully capture the complexity of real-world clinical trial data, and it lacks real-world clinical trial evaluation [14](https://arxiv.org/pdf/2506.00555v1). The wider field of RL-based MLLMs is a rapidly advancing area, with efforts focusing on enhancing reasoning abilities by optimizing reasoning trajectories and aligning multimodal information [15](https://www.semanticscholar.org/paper/4b2e85aae0ded21da525fd1de93444f63b6f70bc), [16](https://www.semanticscholar.org/paper/dd3ad0b37c2aa78ee347b04b7593b1330ff01f7f), [17](https://www.semanticscholar.org/paper/54bd6de7ef903ca59460f5cdd410548893ede9e5), [18](https://www.semanticscholar.org/paper/6dcce2904767e1e9fa5c795cd77b181ebd1b5ae3), [19](https://www.semanticscholar.org/paper/bb26c61cbe322a4f8cf81e8e461d680a5ff05923), [20](https://www.semanticscholar.org/paper/945082498d29f3f88882da6d09a20e5aefb83cb5), [21](https://www.semanticscholar.org/paper/b5b3534158695d26392befb1c0f0719950cd8cda), [22](https://www.semanticscholar.org/paper/9f099be6ea91146da05cebc2b441fb2ddd94d2ce), [23](https://www.semanticscholar.org/paper/1585c43b9c584854bcb42ce4e56416c6b3bc54f3), [24](https://www.semanticscholar.org/paper/131cc450acb014d5e679860fd8902590326d2d67), [25](https://www.semanticscholar.org/paper/cae8cdae8df2600c578312f1a2ac431537292d5d), [26](https://www.semanticscholar.org/paper/c35496f169173c5ab085c7715da69d54b0b3071e), [27](https://www.semanticscholar.org/paper/5f145bd0636027e192d7c8d0102806166fc30d64), [28](https://www.semanticscholar.org/paper/3c27f1433f893bf8071bd0e0a6d8ac5a860d81ee), [29](https://www.semanticscholar.org/paper/8f2eef2e8df6d9e1bc9b73df30fe7956c27faeb4).

**QoQ-Med** introduces an open generalist clinical foundation model that jointly reasons across medical images, time-series signals, and text reports [30](https://arxiv.org/pdf/2506.00711v1). Trained with Domain-aware Relative Policy Optimization (DRPO), it effectively integrates diverse data modalities and improves diagnostic performance, particularly in understudied modalities. Its interpretability features, such as highlighting salient regions, could significantly aid in monitoring patient responses and identifying adverse events during trials, speeding up diagnostic and analytical processes. While QoQ-Med fosters reproducibility through open-source release, its sample efficiency for reasoning processes needs further improvement. Challenges related to model deployment, including data privacy, security, and regulatory approval in diverse clinical settings, remain unaddressed in the study [30](https://arxiv.org/pdf/2506.00711v1).

Lastly, **AMIE (Articulate Medical Intelligence Explorer)** showcases a significant advancement in conversational diagnostic AI by integrating multimodal reasoning into chat-based consultations [31](https://arxiv.org/pdf/2505.04653v1). The system processes skin photos, ECGs, and clinical documents, demonstrating improved diagnostic accuracy compared to primary care physicians in simulated scenarios. This technology holds potential for automating patient screening and data gathering in clinical trials, optimizing patient selection and monitoring. Its state-aware dialogue framework allows for dynamic conversation flow and strategic follow-up questions, emulating experienced clinicians. However, the reliance on simulated consultations, which lack the depth of real-world in-person examinations, necessitates further validation through clinical translation [31](https://arxiv.org/pdf/2505.04653v1). The need for explainable AI to foster trust and collaboration between humans and AI in medical decision-making is a recurring theme across these multimodal models [32](https://www.semanticscholar.org/paper/07d266beef338141705430cce2bdd8419ca90250), [33](https://www.semanticscholar.org/paper/099538285ce1f8e42fbed3e108a530c8673e03cd). Furthermore, multi-agent frameworks are being explored to mimic multidisciplinary clinical decision-making, offering adaptive and robust support [34](https://www.semanticscholar.org/paper/b7aba93de3fe63f59c7f567d61e72cabbc47b369), [35](https://www.semanticscholar.org/paper/519d0d11f208d6f9d6b1f159d25e192e04f0effe).

## Conclusion (AI for Smarter Patient Selection and Trial Enrollment)

The integration of AI, particularly advanced LLMs and multimodal reasoning frameworks, is poised to transform patient selection and trial enrollment in clinical research. Innovations such as AI-powered patient-to-trial matching, contextual phenotyping for homogeneous cohorts, sophisticated methods for identifying predictive biomarkers and individual treatment effects, and comprehensive multimodal diagnostic assistants offer promising pathways to enhance efficiency, reduce costs, and accelerate the development of personalized therapies. While significant progress has been made in automating complex clinical reasoning, processing diverse data types, and providing interpretability, challenges remain. These include ensuring data generalizability across diverse populations and settings, addressing computational demands, mitigating potential biases, and navigating the complex regulatory and ethical landscape for real-world deployment. Continued research focusing on robust validation in live clinical environments and seamless integration into existing healthcare infrastructures will be crucial for realizing the full potential of AI in smarter patient selection and trial enrollment.

# Advancing Causal Inference for Robust Treatment Effect Evaluation

Estimating the true effects of medical treatments in complex, real-world scenarios is fundamental for evidence-based medicine and optimizing clinical trials. Traditional randomized controlled trials (RCTs), while the gold standard, often face limitations in generalizability, cost, and ability to capture dynamic treatment responses. AI-driven causal inference methods are emerging to address these challenges, offering robust approaches to handle real-world data complexities such as distributed datasets, patient non-adherence, time-varying treatments, and unmeasured confounders.

## Privacy-Preserving Causal Inference in Distributed Healthcare Systems

The fragmentation of healthcare data across multiple institutions presents a significant hurdle for large-scale causal effect estimation, primarily due to privacy concerns and regulatory constraints. Federated Causal Inference (FCI) offers a promising solution by enabling multi-site treatment effect estimation without requiring the sharing of individual-level data. The review by Li et al. introduces a comprehensive taxonomy of FCI methods, emphasizing optimization-based frameworks like FedProx-style regularization [36](https://arxiv.org/pdf/2505.02238v1). FedProx operates by having each local site optimize its model with a proximal penalty that encourages its parameters to remain "close" to a global model. This approach stabilizes convergence and achieves near-optimal bias-variance trade-offs, making it particularly valuable for combining heterogeneous datasets from diverse patient populations in multi-site clinical trials while protecting sensitive patient data [36](https://arxiv.org/pdf/2505.02238v1). This differs from traditional meta-analysis, which can fail under positivity violations at individual sites, by leveraging data heterogeneity to improve overlap and estimation [37](https://www.semanticscholar.org/paper/f41bf8196886d56c9614c826602b72968500ae30). Other privacy-preserving methods, such as model-agnostic differentially private causal inference, further decouple nuisance estimation from privacy protection, allowing flexible black-box models while perturbing only predictions and aggregation steps [38](https://www.semanticscholar.org/paper/9f12534ea97cc150ca71362b3682aba0318cf526).

## Enhancing Treatment Effect Estimation Under Non-Adherence

In clinical practice, patients often do not fully adhere to their assigned treatments, complicating the accurate estimation of treatment effects. Chen et al. address this by proposing the Conditional Front-door Adjustment (CFD) for estimating heterogeneous treatment assignment effects (CATEA) under non-adherence [39](https://arxiv.org/pdf/2505.05677v1). While the standard backdoor adjustment (SBD) ignores actual treatment intake, CFD explicitly leverages this information. Theoretically and empirically, CFD demonstrates lower-variance estimates compared to SBD, especially when the true effect of treatment assignment is small, a common scenario in real-world clinical settings. To implement CFD efficiently, the authors introduce LobsterNet, a multi-task neural network. LobsterNet jointly models the multiple nuisance parameters required by CFD (probability of treatment assignment, probability of treatment intake given assignment, and outcome given both assignment and intake) by leveraging shared representations. This joint modeling enhances sample efficiency and reduces estimation error, particularly when the distribution of treatment intake behavior is skewed [39](https://arxiv.org/pdf/2505.05677v1).

## Estimating Sequential Treatment Effects with Unmeasured Confounders

Many clinical conditions require sequential treatment decisions, where current choices influence future patient states and subsequent treatments. A significant challenge here is the presence of unmeasured confounders, latent variables that simultaneously affect treatment assignments and outcomes. Wang et al. introduce the Decomposing Sequential Instrumental Variable (DSIV) framework for CounterFactual Regression (DSIV-CFR) to address this [40](https://arxiv.org/pdf/2505.09113v1). DSIV-CFR uses a transformer architecture to capture long-term dependencies in time series data. Its core mechanism for deconfounding relies on the negative control assumption, treating instrumental variables (IVs) as special negative control exposures and previous outcomes as negative control outcomes. The framework identifies and learns representations of IVs and confounders from observed historical data (`¯H t−1`) using a module (`ψ`) that feeds into representation heads (`ϕZ` for IVs, `ϕC` for confounders). This learning is optimized through a mutual information loss (`LM I`, Equation 15), which ensures that IV representations are correlated with treatment but conditionally independent of the outcome given other variables, thus satisfying IV conditions. Simultaneously, confounder representations are learned to capture influences on both treatment and outcome. The framework then employs a Generalized Method of Moments (GMM) module for counterfactual regression. A second transformer (`h`) predicts potential outcomes, and an adversarial loss (`Ladv`, Equation 18) with a "bridge function" (`f`) is optimized. This adversarial process aims to make the residuals of the outcome prediction model orthogonal to the learned IVs, effectively isolating the direct causal effect from the bias introduced by unmeasured confounders. This modular design provides a robust and scalable approach for sequential treatment effect estimation, suitable for personalized medicine and adaptive trial designs [40](https://arxiv.org/pdf/2505.09113v1). This aligns with efforts to estimate long-term individual causal effects by identifying latent confounders through data heterogeneity [41](https://www.semanticscholar.org/paper/8db7c516535310183746fade7a6c68874b43cb80) and methods that use limited RCT data alongside large observational datasets to mitigate hidden confounders [42](https://www.semanticscholar.org/paper/640e7f89c751c463cbb60b763c24d4c4e51e2564). Proxy-based methods also offer practical tools for overcoming unmeasured confounding in EHR studies [43](https://www.semanticscholar.org/paper/841046da73e7b2bb4eb2b4cb370ed26e49e4a808), [44](https://www.semanticscholar.org/paper/51d1422c9ed0148da712a1af8334b66d5446ebf2).

## Causal Inference for Time-Varying Treatments and Survival Outcomes

Survival analysis, focusing on time-to-event outcomes, introduces additional complexities like censoring and dynamic treatment-confounder feedback. Abraich presents TV-SurvCaus, a novel framework that synergizes representation balancing with recurrent sequence modeling for causal survival analysis under time-varying treatments [45](https://arxiv.org/pdf/2505.01785v1). The model addresses the challenge of treatment-confounder feedback, where past treatments influence time-dependent confounders, which in turn affect future treatment decisions and outcomes. TV-SurvCaus mitigates this by:
1.  **Representation Balancing:** Aims to learn balanced time-dependent representations of patient states across different treatment sequences. This involves an explicit mechanism within the neural architecture that integrates recurrent networks to capture temporal context and minimize representation imbalance, thereby reducing selection bias at the representation level.
2.  **Sequential Stabilized Weights:** The framework incorporates stabilized inverse probability of treatment weighting (IPTW) to re-weight observations, creating a pseudo-population where treatment assignment is effectively randomized over time. This component directly addresses time-varying confounding.
The synergy between representation balancing and sequential stabilized weights allows TV-SurvCaus to distinguish and address different sources of bias: representation balancing tackles selection bias by ensuring covariate distributions are comparable across treatment groups in the learned latent space, while stabilized weights adjust for time-varying confounding that arises from treatment-confounder feedback in the observed data. This dual adjustment improves the reliability of individualized treatment effect estimation and counterfactual survival predictions, crucial for developing adaptive treatment strategies in clinical trials [45](https://arxiv.org/pdf/2505.01785v1). Other advancements in survival analysis include orthogonal survival learners robust to low overlap and censoring [46](https://www.semanticscholar.org/paper/274bbf387692673fb1fee244330e02afabaa8218) and continuous-time marginal structural models to account for irregular visit times and cumulative exposure in real-world data [47](https://www.semanticscholar.org/paper/a2d764b6ffba33df9ab263dcc7ac02a35ef7a740).

## Leveraging Knowledge Graphs for Causal Discovery

Beyond statistical adjustment, integrating domain-specific knowledge can significantly enhance causal inference. Toonsi et al. introduce Causal Knowledge Graphs (CKGs) to identify adverse drug effects (ADRs) [48](https://arxiv.org/pdf/2505.06949v1). CKGs extend traditional knowledge graphs by incorporating formal causal semantics, allowing for principled causal inference and deductive reasoning. The authors construct a Drug-Disease CKG (DD-CKG) that integrates pathways, drug indications, side-effects, and disease classifications. This structured knowledge enables automated, large-scale mediation analysis. By explicitly marking causal edges within the CKG, the framework can deconfound relationships and formulate hypotheses aligned with encoded and entailed background knowledge. The mediation analysis, performed on cohorts like UK Biobank and MIMIC-IV, tests whether drugs mediate effects between indications and downstream disease progression, adjusting for confounders inferred directly from the DD-CKG. This approach successfully reproduces known ADRs and identifies previously undocumented candidate adverse effects, offering a generalizable, knowledge-driven framework for pharmacovigilance and drug safety monitoring. This signifies a move towards incorporating explicit causal knowledge as an inductive bias in causal models, potentially preventing spurious interactions and improving accuracy [49](https://www.semanticscholar.org/paper/09bca14c37c1ca78416406d3d11e80080429bd89), [50](https://www.semanticscholar.org/paper/77b99b31f318edf64110a1ce3d8bd3db82dc2b3b).

## Optimizing Treatment Allocation and Adaptive Experimentation

Traditional clinical trial designs often struggle with efficiency and ethical considerations, especially when dealing with complex patient networks or unknown treatment responses. Faruk et al. propose cluster-based Multi-Armed Bandit (MAB) algorithms to efficiently estimate total treatment effects in networked environments while maximizing expected reward [51](https://arxiv.org/pdf/2505.04200v1). The key challenge in networks is interference (spillover effects), which violates the Stable Unit Treatment Value Assumption (SUTVA). By first identifying and leveraging clusters within the network, the MAB algorithms can adaptively assign treatments within these clusters. This clustering strategy helps to mitigate interference by ensuring that treatment assignments within a cluster are more isolated from those in other clusters, allowing for a more accurate estimation of causal effects while balancing exploration (trying new treatments) and exploitation (using known effective treatments). This dynamic adaptation minimizes the number of participants exposed to less effective treatments, enhancing trial efficiency and patient outcomes [51](https://arxiv.org/pdf/2505.04200v1).

Complementing this, Ek and Zachariah introduce a certifiable learning method for treatment allocation that controls "treatment risk" – the proportion of patients receiving a treatment without benefit – under partial identifiability [52](https://arxiv.org/pdf/2505.08378v1). This method focuses on minimizing overall risk while providing probabilistic guarantees on the controlled treatment risk, which is crucial for ethical and safe precision medicine. It addresses partial identifiability by depending on the accurate estimation of "miscalibration degrees" (Γ). By selecting a suitable Γ, the method ensures that the learned fast-and-frugal decision tree policies are robust even with incomplete or uncertain data, contributing to safer and more optimized clinical trial designs, particularly for personalized medicine [52](https://arxiv.org/pdf/2505.08378v1). These advancements align with broader efforts in adaptive experimentation, such as adaptive, multiply-robust estimators for instrumental variable settings with variance-optimal assignment [53](https://www.semanticscholar.org/paper/353ffa37167c1a43487faa766fd2c644d118db2) and deconfounded warm-start Thompson sampling to leverage observational data for efficient adaptive trials [54](https://www.semanticscholar.org/paper/ff505d99d2fb1673f1a41dfe26deeb573ef1a600). Similarly, frameworks for estimating distributional treatment effects under covariate-adaptive randomization further enhance precision in trial designs [55](https://www.semanticscholar.org/paper/c8e1a0efae9b7e7ffe6774205ba90941e7d70467).

## Conclusion (Advancing Causal Inference)

The landscape of causal inference for robust treatment effect evaluation is rapidly evolving, driven by the need to derive more precise and reliable insights from complex real-world data. Innovations in federated learning enable privacy-preserving multi-site analyses [36](https://arxiv.org/pdf/2505.02238v1), while new methods address critical challenges like patient non-adherence by refining adjustment techniques [39](https://arxiv.org/pdf/2505.05677v1). Advances in sequential treatment effect estimation with unmeasured confounders, leveraging transformer architectures, instrumental variables, and negative controls, promise more accurate personalized treatment strategies [40](https://arxiv.org/pdf/2505.09113v1). Furthermore, synergistic approaches combining representation balancing and sequential weighting are enhancing causal analysis for time-varying treatments and survival outcomes [45](https://arxiv.org/pdf/2505.01785v1). The integration of formal causal semantics into knowledge graphs is opening new avenues for automated drug effect discovery and pharmacovigilance [48](https://arxiv.org/pdf/2505.06949v1). Finally, adaptive learning algorithms are optimizing treatment allocation policies and trial designs by accounting for network interference and controlling treatment risk [51](https://arxiv.org/pdf/2505.04200v1), [52](https://arxiv.org/pdf/2505.08378v1).

Despite these significant strides, challenges remain, particularly in fully satisfying strong causal assumptions, managing computational complexity, and ensuring model interpretability for clinical adoption. Future research will likely focus on developing more assumption-light methods [41](https://www.semanticscholar.org/paper/8db7c516535310183746fade7a6c68874b43cb80), [56](https://www.semanticscholar.org/paper/ab1cdc803561f79fd5303265c6f289ed40f19b1d), incorporating diverse data types and complex outcome distributions [57](https://www.semanticscholar.org/paper/7e821ab0513faf7425663e5d769d5a2cf2130367), [58](https://www.semanticscholar.org/paper/2dd809014f676593615976e1dc0182b3120b4ca5), and further automating causal effect estimation [59](https://www.semanticscholar.org/paper/22de6bbc648fd723db7c12bb2ad7d9d95e70b7c0), [60](https://www.semanticscholar.org/paper/55586284afcecbd4e86f2a96b957be315a819b00). These ongoing advancements are crucial for translating complex data into actionable clinical insights, ultimately leading to more precise, ethical, and effective healthcare interventions.

# Secure Data Collaboration, Synthetic Data, and Trustworthy AI

The accelerating digitalization of healthcare has underscored a critical tension between the immense potential of artificial intelligence (AI) to transform clinical research and the inherent challenges of data privacy, scarcity, and the imperative for trustworthy models. This section explores recent advancements addressing these issues through secure data collaboration, high-fidelity synthetic data generation, and methodologies for ensuring AI reliability and interpretability.

## Secure Data Collaboration through Federated Learning

Traditional centralized machine learning models in healthcare are frequently hampered by stringent privacy regulations (e.g., HIPAA, GDPR) and administrative fragmentation, leading to data remaining in isolated silos [36](https://arxiv.org/pdf/2505.02238v1). Federated Learning (FL) emerges as a robust paradigm to overcome these barriers, enabling collaborative model training across multiple institutions without the direct sharing of sensitive individual-level data. Each site trains a local model on its own data, and only model updates (e.g., gradients or parameters) are shared and aggregated to form a global model, thereby preserving data privacy [61](https://arxiv.org/pdf/2505.08085v1).

A significant development in this domain is **Federated Causal Inference (FCI)**, which extends FL principles to estimate treatment effects across decentralized data sources. This approach is particularly valuable for generating real-world evidence (RWE) from diverse patient populations, critical for improving clinical trials. Research indicates that optimization-based methods, such as FedProx-style regularization, offer near-optimal bias-variance trade-offs in FCI, outperforming naive averaging and meta-analysis methods when dealing with data heterogeneity across sites [36](https://arxiv.org/pdf/2505.02238v1). However, the computational intensity of such optimization-based methods and the lack of standardized federated datasets remain practical challenges for widespread adoption [36](https://arxiv.org/pdf/2505.02238v1).

Further enhancing the security and efficiency of distributed clinical trial data analysis, the **Blockchain-Enabled Federated Edge Learning (BFEL) framework** integrates blockchain technology with advanced FL techniques like FedCurv [62](https://arxiv.org/pdf/2506.00416v1). FedCurv utilizes second-order information (Fisher Information Matrix) to handle heterogeneous and non-IID data more effectively, improving model convergence and reducing communication rounds. Blockchain ensures the integrity, verifiability, and auditability of model aggregation, which is crucial for clinical validation and trust [62](https://arxiv.org/pdf/2506.00416v1). While promising for encouraging participation and accelerating trial results, the computational overhead of second-order methods and the complexity of integrating blockchain infrastructure require careful management for large-scale clinical trials [62](https://arxiv.org/pdf/2506.00416v1). Similar efforts are being explored in privacy-preserving robotic-assisted surgery, where Federated Deep Reinforcement Learning (FDRL) incorporates secure aggregation, differential privacy, and homomorphic encryption to achieve substantial reductions in privacy leakage while maintaining surgical precision [63](https://www.semanticscholar.org/paper/99989716d3e8743e9e6b6f94f1eaec4a0d76c08a).

Beyond neural networks, a **Federated Random Forest solution** has been proposed to fill a gap in existing FL frameworks that primarily support gradient-based models [61](https://arxiv.org/pdf/2505.08085v1). Random Forests offer inherent interpretability, which is vital in clinical settings where understanding decision-making processes is paramount. This framework allows multiple institutions to collaboratively train Random Forest models on local data using secure computation, maintaining competitive predictive accuracy (within 9% of centralized methods) while respecting privacy [61](https://arxiv.org/pdf/2505.08085v1). This highlights a common trade-off in FL: competitive accuracy often comes with a degree of degradation compared to centralized approaches, particularly with increased data fragmentation or heterogeneity [61](https://arxiv.org/pdf/2505.08085v1). The need for further refinement of aggregation strategies and personalized learning in such settings is acknowledged. Other FL applications span various medical domains, including oncology and cancer diagnosis [64](https://www.semanticscholar.org/paper/a1c3ebc807648c068b446870e1b0748cf2a3a96b), liver disease prediction [65](https://www.semanticscholar.org/paper/f0647f9b2cedba95500bb472dd1a1359ac737819), and diabetes prediction [66](https://www.semanticscholar.org/paper/2925179a6fb06afa9e4f3402124ae4d9a146daf5), consistently demonstrating the balance between privacy preservation and model performance.

Addressing the critical issue of algorithmic bias, the **FedIDA (Federated Learning for Imbalance and Disparity Awareness) framework** enhances the fairness of clinical trial models in an FL setting [67](https://arxiv.org/pdf/2505.09295v1). By combining fairness-aware regularization with group-conditional oversampling, FedIDA mitigates biases arising from imbalanced and demographically skewed data. This leads to improved fairness metrics (e.g., DPD, DPR) while sustaining competitive predictive performance, promoting more inclusive and representative models across diverse patient populations [67](https://arxiv.org/pdf/2505.09295v1). However, its reliance on predefined sensitive attributes and the propagation of underlying FL framework limitations pose challenges [67](https://arxiv.org/pdf/2505.09295v1).

Broader advancements in FL include handling noisy and incomplete data through confidence-weighted filtering and GAN-based completion [68](https://www.semanticscholar.org/paper/ccc8216359874d5c2b2112a7f0feddbb40e4a1e6), improving communication efficiency via soft-label caching and sharpening for federated distillation [69](https://www.semanticscholar.org/paper/6e2ee56c63f69cb94ecec92333f378461dc56bf1), and exploring personalized optimization methods like Fed-APO using meta-learning for non-IID healthcare data [70](https://www.semanticscholar.org/paper/201be4e27b0169c1c52dabef8bff2e23b39f824c). The integration of Parameter-Efficient Fine-Tuning (PEFT) methods within FL environments is also emerging as a way to adapt large foundation models to specific tasks efficiently [71](https://www.semanticscholar.org/paper/9c381e4cd9234546c5c95fdd9fe328ff78d42d42), including for localized Retrieval-Augmented Generation (RAG) systems to enhance LLM accuracy with private data [72](https://www.semanticscholar.org/paper/4eb4edc7d0bea4216b1004c6605dd4f8850b69ed). These developments underscore a concerted effort to make FL more robust, efficient, and applicable to complex, real-world clinical scenarios, including adaptive noise adjustment for differential privacy to balance compliance and performance in diverse clinical settings [73](https://www.semanticscholar.org/paper/ffe322720ec348e0501b42a63b0fe00fb5d10c36), and frameworks for one-shot FL to reduce communication overhead [74](https://www.semanticscholar.org/paper/0e0a2db55884f82de43b3741cfd28ed53942eca6).

## Augmenting Data through High-Fidelity Synthetic Generation

Data scarcity and privacy concerns also hinder the development of robust AI models. Synthetic data generation offers a promising solution by mimicking real-world data's statistical properties while safeguarding sensitive information [75](https://arxiv.org/pdf/2505.05019v1).

Research into generating reliable synthetic clinical trial data highlights that **hyperparameter optimization (HPO)** significantly improves data quality, with compound metric optimization strategies outperforming single-metric approaches [75](https://arxiv.org/pdf/2505.05019v1). Crucially, HPO alone is insufficient; integrating explicit domain-specific constraints and robust preprocessing/postprocessing techniques is essential to ensure the clinical validity of synthetic data [75](https://arxiv.org/pdf/2505.05019v1). This allows for enhancing data availability, aiding algorithm development, and optimizing trial design, especially for rare diseases or challenging data collection scenarios [75](https://arxiv.org/pdf/2505.05019v1). Similar efforts are seen in generating synthetic EHRs using VAE frameworks to balance statistical fidelity and data utility for secure sharing [76](https://www.semanticscholar.org/paper/c701997be98f702f3ea57c1f4ec7d1cd14fff725).

A notable advancement in medical imaging is the **Cardiac Phenotype-Guided CMR Generation (CPGG) framework**, which synthesizes high-quality Cardiac Magnetic Resonance (CMR) data conditioned on cardiac phenotypes [77](https://arxiv.org/pdf/2505.03426v1). This augments training datasets for AI models, improving accuracy and robustness in tasks like automated diagnosis and risk stratification, and accelerating trial efficiency by reducing the need for extensive real-world data collection. CPGG is particularly beneficial for studies on rare cardiac diseases where data is scarce [77](https://arxiv.org/pdf/2505.03426v1). However, the quality of generated data heavily relies on the accuracy of input phenotypes, and computational costs remain a consideration [77](https://arxiv.org/pdf/2505.03426v1).

The broader field of synthetic data generation is rapidly evolving, encompassing diverse modalities like tabular data [78](https://www.semanticscholar.org/paper/62623220ebe64c1ae134c51b73a1ab37667761d5), medical text [79](https://www.semanticscholar.org/paper/9efdd09bb8c967052f7e035f45f4e41fad79c7d0), and computational pathology images [80](https://www.semanticscholar.org/paper/6db9ce714320621672909dc286755cb11cc6f7e4). These efforts aim to provide controlled benchmarking environments for model robustness and fairness, allowing explicit control over factors driving distributional shifts to better understand model generalization failures in multi-site clinical model validation [81](https://www.semanticscholar.org/paper/8315d25e966cb77783da5d43e2aee3fcd9bf58ad). Generative AI is also transforming selection and recommendation systems in healthcare by enabling automated optimization and personalization [82](https://www.semanticscholar.org/paper/7483d3a018915ef891896e2a8e1fcfe441f2143f).

## Ensuring Trustworthy AI

As AI models become increasingly integrated into clinical decision-making, ensuring their reliability, safety, and interpretability is paramount. This necessitates robust methodologies for Uncertainty Quantification (UQ), bias detection, and addressing issues like AI hallucinations.

A comprehensive overview of **Uncertainty Quantification (UQ)** methods highlights their pivotal role in enhancing the robustness, reliability, and interpretability of AI systems in healthcare [83](https://arxiv.org/pdf/2505.02874v1). UQ provides a framework for integrating uncertainty estimates throughout the ML pipeline—from data processing to training and evaluation—thereby facilitating the development of more trustworthy clinical decision support systems. While UQ is crucial for practical deployment and regulatory compliance, the field still grapples with the need for tailored solutions for specific clinical trial challenges and the enhancement of UQ methods' interpretability [83](https://arxiv.org/pdf/2505.02874v1).

The integrity of AI-generated medical text, particularly summaries, is critical for patient safety and clinical decision-making. Research has developed robust methods to detect **hallucinations in medical text summarization**, introducing fact-based approaches and expert-annotated datasets [84](https://arxiv.org/pdf/2506.00448v1). The ability to accurately identify and quantify these critical errors is crucial for the reliability of clinical data, facilitating quicker and more accurate reviews of patient information in trials. These methods also offer interpretable metrics, increasing transparency and trustworthiness [84](https://arxiv.org/pdf/2506.00448v1). However, challenges remain in the generalizability of these detectors across diverse clinical language and the computational expense of LLM-based evaluation methods [84](https://arxiv.org/pdf/2506.00448v1).

Furthermore, addressing intrinsic knowledge deficiencies in large language models (LLMs) is vital for their application in knowledge-intensive domains like medicine. The **SENATOR framework** utilizes structural entropy to quantify uncertainty along knowledge graph paths and Monte Carlo Tree Search to selectively explore areas where an LLM lacks domain-specific knowledge [85](https://arxiv.org/pdf/2505.07184v1). This guides the generation of targeted synthetic data for supervised fine-tuning, improving the factual precision and reliability of LLMs for tasks such as patient screening and adverse effect identification in clinical trials [85](https://arxiv.org/pdf/2505.07184v1). The effectiveness of SENATOR, however, hinges on the quality and completeness of the underlying knowledge graphs [85](https://arxiv.org/pdf/2505.07184v1). The broader use of LLMs in healthcare faces challenges including computational intensity, data biases, and privacy concerns, necessitating advancements in explainable AI (XAI) and multimodal LLMs [86](https://www.semanticscholar.org/paper/a4730fd88d2249de1bed9a0f1a9a7641b1caba8d), [87](https://www.semanticscholar.org/paper/12115434fdfa47869ea6f3c24c5bd82ba99ced65), with emerging interest in smaller, resource-efficient language models (SLMs) for healthcare applications [88](https://www.semanticscholar.org/paper/d0e6b0a43edec2424005ee900c6d657597bd7d16).

In conclusion, advancements in federated learning, synthetic data generation, and trustworthy AI methodologies are collectively shaping a future where clinical research can leverage AI more ethically, scalably, and reliably. These innovations are crucial for overcoming long-standing barriers of data access and privacy, while simultaneously building confidence in AI-driven insights for improved patient care and clinical trial outcomes.

# LLMs for Streamlining Clinical Trial Design and Management

Clinical trial design and management are inherently complex, resource-intensive processes, burdened by vast amounts of scientific literature, intricate regulatory requirements, and the critical need for meticulous data handling and safety monitoring. Large Language Models (LLMs) are emerging as transformative tools, capable of automating and optimizing various stages of these workflows, from initial protocol design and literature review to real-time pharmacovigilance. By enhancing information synthesis, retrieval, document generation, and adverse event monitoring, LLMs promise to significantly increase efficiency, reduce costs, and improve decision-making throughout the clinical trial lifecycle.

## Automating Evidence Synthesis and Literature Review

A fundamental step in clinical trial design is the comprehensive review and synthesis of existing literature to identify research gaps, formulate hypotheses, and establish clinical relevance. This process is traditionally time-consuming and prone to human error. LLMs offer a significant advantage by automating the generation of research documents and systematic review components.

The **FRAME (Feedback-Refined Agent Methodology)** framework, for instance, significantly enhances automated medical paper generation through an iterative refinement process involving Generator, Evaluator, and Reflector agents [89](https://arxiv.org/pdf/2505.04649v1). This tripartite architecture progressively improves content quality by using metric-driven feedback to decompose and synthesize information from medical papers. While FRAME focuses on paper generation, its capacity to synthesize future research directions can directly accelerate the literature review phase for clinical trials, aiding researchers in rapidly consolidating existing knowledge and identifying promising avenues. However, FRAME's effectiveness is constrained by its reliance on the quality of initial retrieval and its limitation to offline datasets, meaning it cannot dynamically incorporate the absolute latest research, a critical aspect in fast-evolving medical fields [89](https://arxiv.org/pdf/2505.04649v1).

Complementing this, LLMs can streamline the creation of precise Boolean queries, a cornerstone of systematic reviews essential for identifying relevant literature. Research by Wang et al. demonstrates that careful model selection and prompt design are paramount for LLMs to generate high-quality queries that achieve higher recall rates, thus making the systematic review process faster and more comprehensive [90](https://arxiv.org/pdf/2505.07155v2). This capability is further reinforced by the PROMPTHEUS pipeline, which automates key systematic literature review stages, including systematic searches, data extraction, and topic modeling, significantly reducing manual workload and review time [91](https://www.semanticscholar.org/paper/b81dcd32fbf9bcef7a5314cf94466251dd3b7d3e). Similarly, XSum, a modular pipeline for multi-document summarization, utilizes a question-generation module and an editor module to synthesize retrieved content into coherent and cited summaries, directly applicable to scientific literature synthesis in trial planning [92](https://www.semanticscholar.org/paper/088381cf6f58cbf7b4ebac4086c32c778b4a4877). The ability of LLMs to generate verifiable text and citations, as explored by MedCite [93](https://www.semanticscholar.org/paper/4082c099c95320a1938fda1e4bc195e30b45c6d2) and Valsci [94](https://www.semanticscholar.org/paper/13e079da1dba19509dfd1fd05440b1a52666603a), addresses the critical concern of factual accuracy and hallucination in automated scientific writing.

Beyond query generation, extracting specific evidence from biomedical studies, especially when dealing with conflicting findings, remains a significant challenge. The **URCA (Uniform Retrieval Clustered Augmentation)** framework, supported by the `COCHRANEFOREST` dataset, offers a promising approach for query-driven, document-level scientific evidence extraction [95](https://arxiv.org/pdf/2505.06186v1). By outperforming existing methods in handling conflicting evidence, URCA directly contributes to more efficient and accurate evidence synthesis for clinical trial design, potentially reducing the time and cost associated with systematic reviews. A limitation, however, is the dataset's lack of rationale annotations, hindering interpretability and comprehensive error analysis [95](https://arxiv.org/pdf/2505.06186v1).

## Enhanced Information Retrieval and Data Management with RAG

The integration of external knowledge into LLM outputs, often achieved through Retrieval-Augmented Generation (RAG) systems, is crucial for improving factual accuracy and reducing hallucinations, especially in knowledge-intensive domains like healthcare [96](https://www.semanticscholar.org/paper/5879575701b9b65b5cc56c00d9eebbfa219e0428). RAG systems are particularly valuable in clinical trials for precise information retrieval from vast medical texts, patient records, and trial documentation.

Optimizing RAG system performance involves fine-tuning hyperparameters to balance retrieval quality and computational efficiency. Ammar et al. provide insights into these trade-offs, showing that while vector stores like Chroma may offer faster query processing, Faiss can yield higher retrieval precision [97](https://arxiv.org/pdf/2505.08445v1). Their work also highlights the impact of chunking policies (e.g., naive fixed-length chunking vs. semantic segmentation) and re-ranking on output quality and runtime. For clinical decision support, where accuracy is paramount, these optimizations can lead to more relevant and reliable information retrieval from clinical trial data, ultimately supporting better patient care decisions [97](https://arxiv.org/pdf/2505.08445v1). The ongoing research into advanced chunking strategies, such as late chunking and contextual retrieval, further aims to preserve global context and semantic coherence in RAG systems, crucial for complex clinical documents [98](https://www.semanticscholar.org/paper/ecaa4c26cebc4d53e1712c2ab2a2c82e3861b9b1). Additionally, integrating knowledge graphs, as explored by ConTextual [99](https://www.semanticscholar.org/paper/36bf667b489fc59ef684913a5f535f4949ca7584) and GraphRAG [100](https://www.semanticscholar.org/paper/573721af3692834841c3e82303a3bfabb98423b9), can enhance both linguistic coherence and clinical fidelity by providing structured, domain-specific knowledge to LLMs.

The development of specialized, open-source LLMs tailored for healthcare applications, such as the **Aloe Family models**, represents a significant step towards practical deployment in clinical settings [101](https://arxiv.org/pdf/2505.04388v1). Built on robust base models and optimized with techniques like Direct Preference Optimization (DPO) and RAG, these models demonstrate competitive performance across various healthcare benchmarks. Their open-source nature promotes transparency, reproducibility, and community-driven improvement, enabling researchers to adapt them for diverse clinical trial tasks, including automated patient screening, protocol assistance, and outcome analysis. However, the models' reliance on existing benchmarks may not fully capture the nuances of real-world clinical applications, and their potential to inherit biases from training datasets necessitates careful validation [101](https://arxiv.org/pdf/2505.04388v1).

The broader field of RAG in biomedicine is continually evolving, with surveys identifying various techniques (Naive RAG, Advanced RAG, Modular RAG), highlighting the prevalence of proprietary models, and underscoring the lack of standardized evaluation frameworks and ethical considerations [96](https://www.semanticscholar.org/paper/5879575701b9b65b5cc56c00d9eebbfa219e0428), [102](https://www.semanticscholar.org/paper/ea2f72b979e2646dec92a9ce9b6b07dd0a20e789). Efforts like RAGEv provide evaluation tools and benchmark datasets to assess RAG system accuracy and veracity in healthcare documents [103](https://www.semanticscholar.org/paper/78452726f73fa58e22391cc8b3b7819f38fc24bf).

## Improving Pharmacovigilance and Safety Monitoring

Patient safety is paramount in clinical trials, requiring robust systems for identifying, summarizing, and reporting Adverse Drug Events (ADEs). LLMs offer promising solutions for automating parts of pharmacovigilance. The **GASCADE (Grouping and Abstractive Summarization of Cancer Adverse Drug Events)** framework exemplifies this by providing a structured, summarized view of patient-reported ADEs, specifically in the context of cancer pharmacovigilance [104](https://arxiv.org/pdf/2505.04284v1). GASCADE combines LLM information extraction with the summarization power of encoder-decoder models, enhanced by DPO, to group ADEs by drug and severity. This capability can accelerate safety data analysis, enabling quicker identification of potential drug risks and informing real-time decisions on dose adjustments or trial modifications. A key limitation is its current focus on cancer drugs, restricting generalizability, and its reliance on data from online forums, which may introduce biases and inaccuracies [104](https://arxiv.org/pdf/2505.04284v1). The generation of high-quality synthetic data for such tasks is a recognized challenge, with ongoing research focusing on mitigating hallucinations and factual inconsistencies [79](https://www.semanticscholar.org/paper/9efdd09bb8c967052f7e035f45f4e41fad79c7d0), [105](https://www.semanticscholar.org/paper/b1afad9875b76d2746c9c1bcad2c693110920987).

## Addressing LLM Limitations and Future Directions

Despite their immense potential, LLMs face inherent challenges, including factual inaccuracies (hallucinations), reliance on outdated knowledge, and a lack of transparency in their reasoning, particularly in high-stakes domains like healthcare [96](https://www.semanticscholar.org/paper/5879575701b9b65b5cc56c00d9eebbfa219e0428), [97](https://arxiv.org/pdf/2505.08445v1). To overcome these, approaches like **SENATOR (Structural Entropy-guided Knowledge Navigator)** are being developed to detect and repair knowledge deficiencies in LLMs [85](https://arxiv.org/pdf/2505.07184v1). By using structural entropy and Monte Carlo Tree Search to identify "blind spots" in an LLM's knowledge graph, SENATOR generates targeted synthetic data for fine-tuning, leading to improved factual precision in knowledge-intensive domains such as medicine. This could enhance the accuracy of LLMs used in patient selection criteria or trial result analysis by ensuring they are equipped with comprehensive domain-specific knowledge. However, SENATOR's effectiveness is contingent on the quality and completeness of the underlying knowledge graphs, and the clinical relevance of improved LLM performance still requires additional evaluation [85](https://arxiv.org/pdf/2505.07184v1).

The broader adoption of LLMs in clinical trials necessitates robust evaluation frameworks, as highlighted by a survey on RAG system evaluation that emphasizes the need for domain-specific datasets and a balance between automated and human judgment [106](https://www.semanticscholar.org/paper/1cdbb922dcc977100e381a5debedb37994d27363). Furthermore, ethical considerations, including patient privacy and data security, are paramount and must be addressed rigorously for responsible and effective deployment [96](https://www.semanticscholar.org/paper/5879575701b9b65b5cc56c00d9eebbfa219e0428), [101](https://arxiv.org/pdf/2505.04388v1). Future research will likely focus on developing more resource-efficient models, such as Small Language Models (SLMs) [88](https://www.semanticscholar.org/paper/d0e6b0a43edec2424005ee900c6d657597bd7d16), and enhancing multimodal reasoning capabilities to integrate various data types, ensuring practical deployment in real-world clinical settings [13](https://www.semanticscholar.org/paper/fd1d271d0cb4aba04aea8a495cfb2f85e03ac310).

In conclusion, LLMs offer a profound opportunity to streamline clinical trial design and management through automated evidence synthesis, enhanced information retrieval, and improved pharmacovigilance. While current research demonstrates significant advancements, successful real-world deployment hinges on addressing critical limitations related to data quality, generalizability, ethical considerations, and the development of robust, transparent validation methodologies. Continued interdisciplinary collaboration between AI researchers and clinical experts will be essential to fully realize the transformative potential of LLMs in accelerating medical innovation and improving patient outcomes.

# AI for Real-time Monitoring and Adaptive Trial Interventions

AI-driven real-time monitoring and adaptive interventions are increasingly vital for modernizing clinical trials, enabling proactive safety measures, quicker identification of adverse events, and more data-driven adjustments to treatment plans. This section explores two significant advancements in this domain: an AI system for early patient deterioration detection using wearable data, and a novel probabilistic model for analyzing continuously evolving biomarker distributions.

Early detection of patient deterioration, particularly in critical care settings, is paramount for reducing mortality rates. Traditional monitoring systems can be limited, and unnoticed changes can delay crucial interventions. Addressing this, TARL (Transition-Aware Representation Learning) [107](https://arxiv.org/pdf/2505.01305v1) introduces an innovative machine learning approach for automated patient monitoring using real-time heart rate data from wearable devices. The core of TARL's methodology lies in its **shapelet analysis**, where shapelets are identified as characteristic time-series subsequences that offer clear, explanatory insights into heart rate patterns. To capture the dynamic relationships and progression of illness, TARL constructs a **shapelet-transition knowledge graph**. This graph models the sequential patterns and transitions between different heart rate shapelets, providing a structured representation of a patient's evolving condition. Furthermore, TARL employs a **transition-aware knowledge embedding** technique, which uses an attention mechanism and incorporates "transition confidence" to robustly handle missing data—a common challenge with wearable devices—while reinforcing the relationships between shapelets. This allows TARL to detect patient deterioration approximately six hours in advance, falling within the critical "golden window" for many treatments, thereby potentially improving patient outcomes and accelerating clinical trial timelines by identifying adverse events more quickly [107](https://arxiv.org/pdf/2505.01305v1). The model's inherent explainability, enabling clinicians to understand the basis for predictions, is crucial for fostering trust and facilitating adoption in clinical practice.

Despite its advancements, TARL's generalizability is limited by its reliance on a single-center dataset, and its current focus solely on heart rate data. The broader landscape of AI in healthcare emphasizes the need for systems that can integrate diverse, multimodal data sources [108](https://www.semanticscholar.org/paper/b847ce14966bdb9af77501f0850f45b4411f85e0), [109](https://www.semanticscholar.org/paper/0b58e33e5512543ac6fb3c30644ae8b3a54d76c0). Research like TGAM [108](https://www.semanticscholar.org/paper/b847ce14966bdb9af77501f0850f45b4411f85e0) and MedFusionAI [109](https://www.semanticscholar.org/paper/0b58e33e5512543ac6fb3c30644ae8b3a54d76c0) highlight the benefits of fusing EHR, lab tests, and sensor data for mortality prediction and chronic disease risk. Similarly, addressing challenges posed by irregular time series and missing values, which are prevalent in real-world medical data, is critical [110](https://www.semanticscholar.org/paper/58cd1dc7c95a9d367b822b5e533728b5e25e6bff), [111](https://www.semanticscholar.org/paper/628c0d3d185606195ca1dcb8758ede3621dbe1f7), [112](https://www.semanticscholar.org/paper/ecb0c71c3ff63fa2f706df9079f5e8f144e90955), [113](https://www.semanticscholar.org/paper/d64d108fd7fae6535543de8029bc0e40a02526ea). MIRA [113](https://www.semanticscholar.org/paper/d64d108fd7fae6535543de8029bc0e40a02526ea) and the hybrid STraTS-mTAND [110](https://www.semanticscholar.org/paper/58cd1dc7c95a9d367b822b5e533728b5e25e6bff) offer robust solutions for medical time series forecasting and prediction in the presence of such irregularities. The drive for explainability, as seen in TARL, is also a common theme across predictive models, with techniques like SHAP and LIME enhancing transparency in clinical decision support systems [114](https://www.semanticscholar.org/paper/52398c6bae5d05ce7ea61d7317617252d44eac16), [115](https://www.semanticscholar.org/paper/0edeb82af75a556a417ee9c571aa3e9f4838745f), [116](https://www.semanticscholar.org/paper/37015ba93122de366399a58dc6d48bfb3a5a1962).

Complementing real-time monitoring, another key area is the continuous analysis of biomarker distributions in clinical trials. A novel probabilistic model, detailed in [117](https://arxiv.org/pdf/2505.08698v1), addresses the challenge of modeling continuous-time dynamics of probability distributions from time-dependent data samples, particularly relevant for biomarkers like glucose in diabetes trials. The model leverages a **mixture of Gaussian distributions** to capture how samples from a continuous-time stochastic process evolve. To model potential distribution shifts over time, it introduces a time-dependent function parameterized by **Neural Ordinary Differential Equations (Neural ODEs)**. Neural ODEs allow for continuous-depth modeling of hidden states, adapting computation to local dynamics, offering parameter efficiency, and yielding smooth latent trajectories, thereby capturing the continuous evolution of component probabilities [117](https://arxiv.org/pdf/2505.08698v1). Crucially, the model is estimated non-parametrically using **Maximum Mean Discrepancy (MMD)**, a semi-metric that quantifies the discrepancy between probability distributions. MMD avoids the strong structural assumptions and serial-correlation issues that often limit likelihood-based methods, enhancing robustness and statistical efficiency. This approach provides improved interpretability and computational efficiency compared to existing methods, enabling the detection of subtle temporal shifts in biomarker distributions. Its application to continuous glucose monitoring (CGM) data demonstrates its utility in rigorously comparing treatment and control groups and characterizing glucose dynamics in ways standard techniques cannot [117](https://arxiv.org/pdf/2505.08698v1).

While powerful, this model's primary focus on glucose data suggests a need for validation across diverse biomarker types and patient populations. The inherent complexity of models involving Gaussian mixtures and Neural ODEs also poses implementation and interpretation challenges for researchers unfamiliar with these advanced techniques. The concept of continuously modeling dynamic processes is further explored in research on medical time series. MIRA [113](https://www.semanticscholar.org/paper/d64d108fd7fae6535543de8029bc0e40a02526ea) and other works leverage Neural ODEs for continuous trajectory modeling and forecasting in medical time series, handling irregular intervals and missing values. Similarly, extensions to Neural ODEs, such as Neural Controlled Differential Equations (Neural CDEs), address the limitation of standard ODEs in updating hidden states as new data arrives over time, crucial for irregularly sampled EHR data. Other methods utilize continuous-time Markov Chains [118](https://www.semanticscholar.org/paper/1ce0fc59a4736fd207ed5b53e15ae78b35ee71a6) or deep learning frameworks for virtual CGM and glucose prediction [119](https://www.semanticscholar.org/paper/c1f1ea9810289b372feb661d21a116a2589e1265). The integration of physiological models with neural networks also shows promise for personalized, real-time health monitoring [120](https://www.semanticscholar.org/paper/6826dd15ee0d08b5118d29b03203625a0f4c40f0).

Collectively, these advancements represent significant strides towards more adaptive and responsive clinical trials. TARL's capacity for early, explainable detection of deterioration empowers clinicians with timely insights for proactive intervention, directly enhancing patient safety and potentially optimizing trial duration. The Neural ODE-based model for biomarker dynamics offers a sophisticated tool for understanding the nuanced effects of interventions on physiological states, leading to more rigorous treatment comparisons and data-driven trial adaptations. Both approaches contribute to overcoming common challenges in healthcare data, such as sparsity, irregularity, and missingness. The ongoing research in multimodal data fusion, robust handling of time-series complexities, and the drive for interpretable AI models will continue to refine these capabilities, paving the way for advanced digital health solutions and personalized medicine strategies within the clinical trial ecosystem, potentially moving towards "digital twins" for individualized simulations [121](https://www.semanticscholar.org/paper/61d78a78cd963df39b0e3408e6f4de3070cd6eaa) and leveraging synthetic data generation for more robust models [122](https://www.semanticscholar.org/paper/63ca8f86de6b2c3299e4fd6fd28e1c24cf040341).

# Spotlight: TrialMatchAI - Revolutionizing Patient Recruitment

Patient recruitment remains a persistent and significant bottleneck in clinical trial execution, often leading to delays, increased costs, and hindering patient access to novel therapies, particularly in precision medicine [1](https://arxiv.org/pdf/2505.08508v1), [123](https://www.semanticscholar.org/paper/cc543eec013f8b3ee878da3d0dc5b11a858960d8). Traditional manual matching processes are labor-intensive, unscalable, and prone to missed opportunities, especially given the increasing complexity of trial eligibility criteria [1](https://arxiv.org/pdf/2505.08508v1). Addressing this challenge, **TrialMatchAI** emerges as an innovative, end-to-end AI-powered system designed to automate and optimize patient-to-trial matching.

TrialMatchAI stands out for its ability to process heterogeneous clinical data, encompassing both structured records and unstructured physician notes, a common yet challenging aspect of real-world clinical data [1](https://arxiv.org/pdf/2505.08508v1), [99](https://www.semanticscholar.org/paper/36bf667b489fc59ef684913a5f535f4949ca7584). The system leverages fine-tuned, open-source Large Language Models (LLMs) within a Retrieval-Augmented Generation (RAG) framework and incorporates Chain-of-Thought (CoT) reasoning to provide detailed, explainable eligibility assessments [1](https://arxiv.org/pdf/2505.08508v1). This design addresses critical needs for transparency and reproducibility in clinical AI applications.

## Underlying Mechanisms and Workflow:

TrialMatchAI's modular architecture orchestrates a sophisticated multi-stage pipeline:

1.  **Data Ingestion and Preprocessing:** The system normalizes biomedical entities from both patient records and trial eligibility criteria. Patient data is standardized using the **Phenopackets** exchange format, which facilitates semantic interoperability and consistent representation of clinical and molecular attributes [1](https://arxiv.org/pdf/2505.08508v1), [4](https://www.semanticscholar.org/paper/ecc3051e19f7713350e0950b6cde1f0841ca2d7c), [124](https://www.semanticscholar.org/paper/aa38b9b16c8102688a1d09050ce0eae2e8d0498c). Named Entity Recognition (NER) models (e.g., fine-tuned BioBERT, RoBERTa-large, GliNER) extract key entities like genes, diseases, and drugs, followed by entity normalization (e.g., BioSyn, GNormPlus) to map them to controlled vocabularies (MeSH, OMIM, UMLS) [1](https://arxiv.org/pdf/2505.08508v1). This step also includes query expansion via a Phi-4 model to enhance search versatility [1](https://arxiv.org/pdf/2505.08508v1). All textual data are converted into high-dimensional dense embeddings using models like BGE-M3 for semantic search [1](https://arxiv.org/pdf/2505.08508v1).

2.  **Candidate Trial Retrieval:** A hybrid search strategy combines lexical (BM25) and semantic (K-Nearest Neighbor, KNN, with HNSW indexing) searches via Elasticsearch [1](https://arxiv.org/pdf/2505.08508v1), [125](https://www.semanticscholar.org/paper/0f8446ae0441b3f4cd5e5db05d667ad67c572ec2). This dual approach ensures that trials are matched based on both explicit keyword overlap and deeper conceptual similarity, mitigating the risk of overlooking relevant trials due to varied phrasing in eligibility criteria [1](https://arxiv.org/pdf/2505.08508v1). Pre-retrieval filtering based on demographics and trial status further refines the initial pool [1](https://arxiv.org/pdf/2505.08508v1).

3.  **LLM-based Re-ranking:** The initial list of candidate trials is refined by a fine-tuned Gemma-2-2B model. This re-ranking process assesses the relevance of individual eligibility criteria to the patient's profile, prioritizing trials with the most pertinent criteria [1](https://arxiv.org/pdf/2505.08508v1). This step is crucial, as highlighted by other research in improving the efficiency of patient screening by prioritizing relevant cases for review [126](https://www.semanticscholar.org/paper/00bd7358bdce4c2992599451e2d316f25397bab4).

4.  **Eligibility Classification and Final Ranking:** The core of TrialMatchAI's reasoning lies in a fine-tuned Phi-4 model that performs criterion-level eligibility assessment using medical Chain-of-Thought (CoT) reasoning [1](https://arxiv.org/pdf/2505.08508v1). CoT reasoning prompts LLMs to generate intermediate logical steps, improving performance on complex tasks and providing a transparent window into the model’s decision-making process [1](https://arxiv.org/pdf/2505.08508v1), [127](https://www.semanticscholar.org/paper/977586e2442843ba13ee9fe902bd86f7548b56aa). For each inclusion or exclusion criterion, the model classifies it as "Met," "Not Met," "Unclear," or "Irrelevant" (or "Violated," "Not Violated" for exclusion criteria), and crucially, generates a detailed, evidence-based justification based *only* on the provided patient information and retrieved context [1](https://arxiv.org/pdf/2505.08508v1). These criterion-level scores are then aggregated to provide a final ranked list of clinical trial recommendations [1](https://arxiv.org/pdf/2505.08508v1).

## Performance and Impact:

TrialMatchAI has demonstrated state-of-the-art performance across synthetic and real-world clinical datasets. In real-world validation on 52 metastatic cancer patients, 92% had at least one relevant trial retrieved within the top 20 recommendations, a clinically practical threshold for oncologists [1](https://arxiv.org/pdf/2505.08508v1). Expert assessment validated over 90% accuracy in criterion-level eligibility classification, particularly excelling in biomarker-driven matches [1](https://arxiv.org/pdf/2505.08508v1). Notably, TrialMatchAI achieves competitive performance using lightweight, open-source models, outperforming some existing AI tools that rely on significantly larger, proprietary GPT models, thus addressing concerns related to cost, transparency, and data privacy [1](https://arxiv.org/pdf/2505.08508v1), [88](https://www.semanticscholar.org/paper/d0e6b0a43edec2424005ee900c6d657597bd7d16).

## Broader Context and Challenges:

The development of TrialMatchAI aligns with a growing trend of integrating LLMs into patient-trial matching systems, which have shown improved accuracy and scalability [123](https://www.semanticscholar.org/paper/cc543eec013f8b3ee878da3d0dc5b11a858960d8), [128](https://www.semanticscholar.org/paper/dad80f36a1b8fa757552c76ced3b6e43e093c6c2), [129](https://www.semanticscholar.org/paper/3b7ee1aec6d1fcdc5bc8d3bb3835659bcc1b53db), [130](https://www.semanticscholar.org/paper/12f9e0f9e00c38e4fbdbfabad8ecc0a9d178ad3d). Systems like OncoLLM [130](https://www.semanticscholar.org/paper/12f9e0f9e00c38e4fbdbfabad8ecc0a9d178ad3d) and other LLM-based platforms [129](https://www.semanticscholar.org/paper/3b7ee1aec6d1fcdc5bc8d3bb3835659bcc1b53db) also emphasize efficiency gains and the ability to process complex oncology data. The reliance on Retrieval-Augmented Generation (RAG) in TrialMatchAI mirrors approaches in other biomedical applications for enhancing factual accuracy and explainability [125](https://www.semanticscholar.org/paper/0f8446ae0441b3f4cd5e5db05d667ad67c572ec2), [131](https://www.semanticscholar.org/paper/f185c99b0af3d7598f751ad977b1898ebcd05c33). The push for explainable outputs is critical, as interpretability and trustworthiness remain significant challenges for LLMs in healthcare [123](https://www.semanticscholar.org/paper/cc543eec013f8b3ee878da3d0dc5b11a858960d8), [132](https://www.semanticscholar.org/paper/55d73c928f98506b438803586382f9a9d8dd98d), [127](https://www.semanticscholar.org/paper/977586e2442843ba13ee9fe902bd86f7548b56aa).

Despite its strengths, TrialMatchAI, like all LLM-based systems, is susceptible to confabulations (hallucinations) and misclassifications, though instances were low in expert evaluations [1](https://arxiv.org/pdf/2505.08508v1), [79](https://www.semanticscholar.org/paper/9efdd09bb8c967052f7e035f45f4e41fad79c7d0). Other limitations include the potential impact of incomplete patient records on accuracy and slower inference speeds compared to larger, proprietary models [1](https://arxiv.org/pdf/2505.08508v1). The reliance on the Phenopackets format, while promoting interoperability, also necessitates data conversion from native formats, which can be an implementation barrier [1](https://arxiv.org/pdf/2505.08508v1).

## Future Outlook:

To mitigate identified limitations, future work on TrialMatchAI includes developing robust flagging and monitoring mechanisms, integrating agentic workflows for output verification, exploring knowledge distillation for efficiency, and using collaborative filtering to address incomplete data [1](https://arxiv.org/pdf/2505.08508v1). These advancements align with the broader research efforts in medical AI to develop more robust, adaptive, and human-centered systems, potentially leveraging multi-agent AI for enhanced clinical reasoning [34](https://www.semanticscholar.org/paper/b7aba93de3fe63f59c7f567d61e72cabbc47b369), [133](https://www.semanticscholar.org/paper/e08574d105b350a5d5a64d4d0cd30316f06bc4f).

In conclusion, TrialMatchAI represents a significant step forward in automating and democratizing access to clinical trials. By combining high accuracy, explainability, and privacy-preserving local deployment with an open-source framework, it sets a new standard for AI-driven clinical trial matching, promising to expedite trial completion and improve patient access to life-saving treatments.

# Conclusion

The presented advancements illustrate a substantial evolution in the application of artificial intelligence across the clinical research continuum. Innovations such as AI-powered patient-to-trial matching, refined phenotyping, and multimodal diagnostics are enhancing the precision of patient selection. Concurrently, sophisticated causal inference methods are improving the reliability of treatment effect evaluation under complex real-world conditions, while federated learning and synthetic data generation address critical challenges in data privacy and scarcity. Large Language Models are proving instrumental in streamlining evidence synthesis, documentation, and pharmacovigilance, and real-time monitoring systems are enabling proactive interventions and dynamic trial adaptations. Despite these strides, common challenges persist, including ensuring generalizability across diverse populations, managing computational resource demands, fostering interpretability for clinical acceptance, and navigating regulatory and ethical landscapes. Future research will focus on developing more assumption-light methodologies, integrating diverse data types, enhancing automation, and conducting robust validation in live clinical environments to fully realize the transformative potential of these AI technologies in accelerating medical progress and improving patient care.

# References

1.  Majd Abdallah, Sigve Nakken, Mariska Bierkens, Johanna Galvis, Alexis Groppi, Slim Karkar, Lana Meiqari, Maria Alexandra Rujano, Steve Canham, Rodrigo Dienstmann, Remond Fijneman, Eivind Hovig, Gerrit Meijer, Macha Nikolski (2025). *TrialMatchAI: An End-to-End AI-powered Clinical Trial Recommendation System to Streamline Patient-to-Trial Matching*. ArXiv:2505.08508v1. [https://arxiv.org/pdf/2505.08508v1](https://arxiv.org/pdf/2505.08508v1)
2.  Jiageng Wu, Bowen Gu, Ren Zhou, Kevin Xie, Doug Snyder, Yixing Jiang, Valentina Carducci, R. Wyss, R. J. Desai, Emily Alsentzer, L. A. Celi, A. Rodman, Sebastian Schneeweiss, Jonathan H. Chen, Santiago Romero-Brufau, K. J. Lin, Jie Yang (2025). *BRIDGE: Benchmarking Large Language Models for Understanding Real-world Clinical Practice Text*. ArXiv:10.48550/arXiv.2504.19467. [https://www.semanticscholar.org/paper/3982dd06568c983e94cd748ddaf123829160ee7e](https://www.semanticscholar.org/paper/3982dd06568c983e94cd748ddaf123829160ee7e)
3.  Shuguang Zhao, Qiangzhong Feng, Zhiyang He, Peipei Sun, Yingying Wang, Xiaodong Tao, Xiaoliang Lu, Mei Cheng, Xinyue Wu, Yanyan Wang, Wei Liang (2025). *EMRModel: A Large Language Model for Extracting Medical Consultation Dialogues into Structured Medical Records*. ArXiv:10.48550/arXiv.2504.16448. [https://www.semanticscholar.org/paper/6d586605660e0351d9e29ce8f6c8fae1c4c271b4](https://www.semanticscholar.org/paper/6d586605660e0351d9e29ce8f6c8fae1c4c271b4)
4.  Komal Gilani, Marlo Verket, Christof Peters, M. Dumontier, Hans-Peter Brunner-La Rocca, V. Urovi (2025). *CDE-Mapper: Using Retrieval-Augmented Language Models for Linking Clinical Data Elements to Controlled Vocabularies*. ArXiv:2505.04365. [https://www.semanticscholar.org/paper/ecc3051e19f7713350e0950b6cde1f0841ca2d7c](https://www.semanticscholar.org/paper/ecc3051e19f7713350e0950b6cde1f0841ca2d7c)
5.  Aditya Nagori, Ayush Gautam, Matthew O. Wiens, Vuong Nguyen, Nathan Kenya Mugisha, Jerome Kabakyenga, Niranjan Kissoon, John Mark Ansermino, Rishikesan Kamaleswaran (2025). *Contextual Phenotyping of Pediatric Sepsis Cohort Using Large Language Models*. ArXiv:2505.09805v1. [https://arxiv.org/pdf/2505.09805v1](https://arxiv.org/pdf/2505.09805v1)
6.  Linshanshan Wang, Mengyan Li, Zongqi Xia, Molei Liu, Tianxi Cai (2025). *Semi-supervised Clustering Through Representation Learning of Large-scale EHR Data*. ArXiv:2505.20731. [https://www.semanticscholar.org/paper/70fcc9b10b76566a93d7a02fbcc8b597c25068c4](https://www.semanticscholar.org/paper/70fcc9b10b76566a93d7a02fbcc8b597c25068c4)
7.  David Svensson, Erik Hermansson, Nikolaos Nikolaou, Konstantinos Sechidis, Ilya Lipkovich (2025). *Overview and practical recommendations on using Shapley Values for identifying predictive biomarkers via CATE modeling*. ArXiv:2505.01145v1. [https://arxiv.org/pdf/2505.01145v1](https://arxiv.org/pdf/2505.01145v1)
8.  Sehwan Kim, Faming Liang (2025). *Extended Fiducial Inference for Individual Treatment Effects via Deep Neural Networks*. ArXiv:2505.01995v1. [https://arxiv.org/pdf/2505.01995v1](https://arxiv.org/pdf/2505.01995v1)
9.  Ke Zhu, Jianing Chu, Ilya Lipkovich, Wenyu Ye, Shu Yang (2025). *Doubly Robust Fusion of Many Treatments for Policy Learning*. ArXiv:2505.08092v2. [https://arxiv.org/pdf/2505.08092v2](https://arxiv.org/pdf/2505.08092v2)
10. Yishan Shen, Yuyang Ye, Hui Xiong, Yong Chen (2025). *SAFER: A Calibrated Risk-Aware Multimodal Recommendation Model for Dynamic Treatment Regimes*. ArXiv:2506.06649. [https://www.semanticscholar.org/paper/b6973a9299073ba8bbea732cb2935e5924a811b2](https://www.semanticscholar.org/paper/b6973a9299073ba8bbea732cb2935e5924a811b2)
11. Hechuan Wen, Tong Chen, Mingming Gong, Li Kheng Chai, Shazia Sadiq, Hongzhi Yin (2025). *Enhancing Treatment Effect Estimation via Active Learning: A Counterfactual Covering Perspective*. ArXiv:2505.05242v1. [https://arxiv.org/pdf/2505.05242v1](https://arxiv.org/pdf/2505.05242v1)
12. Da Wu, Zhanliang Wang, Quan Nguyen, Zhuoran Xu, Kai Wang (2025). *Multimodal Integrated Knowledge Transfer to Large Language Models through Preference Optimization with Biomedical Applications*. ArXiv:2505.05736v1. [https://arxiv.org/pdf/2505.05736v1](https://arxiv.org/pdf/2505.05736v1)
13. Zeyu Liu, Zhitian Hou, Yining Di, Kejing Yang, Zhijie Sang, Congkai Xie, Jingwen Yang, Siyuan Liu, Jialu Wang, Chunming Li, Ming Li, Hongxia Yang (2025). *Infi-Med: Low-Resource Medical MLLMs with Robust Reasoning Evaluation*. ArXiv:2505.23867. [https://www.semanticscholar.org/paper/fd1d271d0cb4aba04aea8a495cfb2f85e03ac310](https://www.semanticscholar.org/paper/fd1d271d0cb4aba04aea8a495cfb2f85e03ac310)
14. Peng Xia, Jinglu Wang, Yibo Peng, Kaide Zeng, Xian Wu, Xiangru Tang, Hongtu Zhu, Yun Li, Shujie Liu, Yan Lu, Huaxiu Yao (2025). *MMedAgent-RL: Optimizing Multi-Agent Collaboration for Multimodal Medical Reasoning*. ArXiv:2506.00555v1. [https://arxiv.org/pdf/2506.00555v1](https://arxiv.org/pdf/2506.00555v1)
15. Guanghao Zhou, Panjia Qiu, Cen Chen, Jie Wang, Zheming Yang, Jian Xu, Minghui Qiu (2025). *Reinforced MLLM: A Survey on RL-Based Reasoning in Multimodal Large Language Models*. ArXiv:10.48550/arXiv.2504.21277. [https://www.semanticscholar.org/paper/4b2e85aae0ded21da525fd1de93444f63b6f70bc](https://www.semanticscholar.org/paper/4b2e85aae0ded21da525fd1de93444f63b6f70bc)
16. Songtao Jiang, Yuan Wang, Ruizhe Chen, Yan Zhang, Ruilin Luo, Bohan Lei, Sibo Song, Yang Feng, Jimeng Sun, Jian Wu, Zuozhu Liu (2025). *CAPO: Reinforcing Consistent Reasoning in Medical Decision-Making*. ArXiv:2506.12849. [https://www.semanticscholar.org/paper/dd3ad0b37c2aa78ee347b04b7593b1330ff01f7f](https://www.semanticscholar.org/paper/dd3ad0b37c2aa78ee347b04b7593b1330ff01f7f)
17. Tan-Hanh Pham, Chris Ngo (2025). *RARL: Improving Medical VLM Reasoning and Generalization with Reinforcement Learning and LoRA under Data and Hardware Constraints*. ArXiv:2506.06600. [https://www.semanticscholar.org/paper/54bd6de7ef903ca59460f5cdd410548893ede9e5](https://www.semanticscholar.org/paper/54bd6de7ef903ca59460f5cdd410548893ede9e5)
18. Shaohao Rui, Kaitao Chen, Weijie Ma, Xiaosong Wang (2025). *Improving Medical Reasoning with Curriculum-Aware Reinforcement Learning*. ArXiv:2505.19213. [https://www.semanticscholar.org/paper/6dcce2904766e1e9fa5c795cd77b181ebd1b5ae3](https://www.semanticscholar.org/paper/6dcce2904766e1e9fa5c795cd77b181ebd1b5ae3)
19. Che Liu, Haozhe Wang, Jiazhen Pan, Zhongwei Wan, Yong Dai, Fangzhen Lin, Wenjia Bai, D. Rueckert, Rossella Arcucci (2025). *Beyond Distillation: Pushing the Limits of Medical LLM Reasoning with Minimalist Rule-Based RL*. ArXiv:2505.17952. [https://www.semanticscholar.org/paper/bb26c61cbe322a4f8cf81e8e461d680a5ff05923](https://www.semanticscholar.org/paper/bb26c61cbe322a4f8cf81e8e461d680a5ff05923)
20. Wenhui Zhu, Xuanzhao Dong, Xin Li, Peijie Qiu, Xiwen Chen, Abolfazl Razi, Aristeidis Sotiras, Yi Su, Yalin Wang (2025). *Toward Effective Reinforcement Learning Fine-Tuning for Medical VQA in Vision-Language Models*. ArXiv:2505.13973. [https://www.semanticscholar.org/paper/945082498d29f3f88882da6d09a20e5aefb83cb5](https://www.semanticscholar.org/paper/945082498d29f3f88882da6d09a20e5aefb83cb5)
21. Zeyu Liu, Yuhang Liu, Guanghao Zhu, Congkai Xie, Zhen Li, Jianbo Yuan, Xinyao Wang, Qing Li, Shing-Chi Cheung, Sheng Zhang, Fei Wu, Hongxia Yang (2025). *Infi-MMR: Curriculum-based Unlocking Multimodal Reasoning via Phased Reinforcement Learning in Multimodal Small Language Models*. ArXiv:2505.23091. [https://www.semanticscholar.org/paper/b5b3534158695d26392befb1c0f0719950cd8cda](https://www.semanticscholar.org/paper/b5b3534158695d26392befb1c0f0719950cd8cda)
22. Boqin Zhuang, Chenxiao Song, Huitong Lu, Jiacheng Qiao, Mingqian Liu, Mingxing Yu, Ping Hong, Rui Li, Xiaoxia Song, Xiangjun Xu, Xu Chen, Yaoyao Ma, Yujie Gao (2025). *WiNGPT-3.0 Technical Report*. ArXiv:2505.17387. [https://www.semanticscholar.org/paper/9f099be6ea91146da05cebc2b441fb2ddd94d2ce](https://www.semanticscholar.org/paper/9f099be6ea91146da05cebc2b441fb2ddd94d2ce)
23. Jaehoon Yun, Jiwoong Sohn, Jungwoo Park, Hyunjae Kim, Xiangru Tang, Yanjun Shao, Yonghoe Koo, Minhyeok Ko, Qingyu Chen, Mark Gerstein, Michael Moor, Jaewoo Kang (2025). *Med-PRM: Medical Reasoning Models with Stepwise, Guideline-verified Process Rewards*. ArXiv:2506.11474. [https://www.semanticscholar.org/paper/1585c43b9c584854bcb42ce4e56416c6b3bc54f3](https://www.semanticscholar.org/paper/1585c43b9c584854bcb42ce4e56416c6b3bc54f3)
24. Songtao Jiang, Yan Zhang, Yeying Jin, Zhihang Tang, Yangyang Wu, Yang Feng, Jian Wu, Zuozhu Liu (2025). *HSCR: Hierarchical Self-Contrastive Rewarding for Aligning Medical Vision Language Models*. ArXiv:2506.00805. [https://www.semanticscholar.org/paper/131cc450acb014d5e679860fd8902590326d2d67](https://www.semanticscholar.org/paper/131cc450acb014d5e679860fd8902590326d2d67)
25. Wataru Kawakami, Keita Suzuki, Junichiro Iwasawa (2025). *Stabilizing Reasoning in Medical LLMs with Continued Pretraining and Reasoning Preference Optimization*. ArXiv:10.48550/arXiv.2504.18080. [https://www.semanticscholar.org/paper/cae8cdae8df2600c578312f1a2ac431537292d5d](https://www.semanticscholar.org/paper/cae8cdae8df2600c578312f1a2ac431537292d5d)
26. Peiyuan Jing, Kinhei Lee, Zhenxuan Zhang, Huichi Zhou, Zhengqing Yuan, Zhifan Gao, Lei Zhu, G. Papanastasiou, Yingying Fang, Guang Yang (2025). *Reason Like a Radiologist: Chain-of-Thought and Reinforcement Learning for Verifiable Report Generation*. ArXiv:10.48550/arXiv.2504.18453. [https://www.semanticscholar.org/paper/c35496f169173c5ab085c7715da69d54b0b3071e](https://www.semanticscholar.org/paper/c35496f169173c5ab085c7715da69d54b0b3071e)
27. Yin Fang, Qiao Jin, Guangzhi Xiong, Bowen Jin, Xianrui Zhong, Siru Ouyang, Aidong Zhang, Jiawei Han, Zhiyong Lu (2025). *Cell-o1: Training LLMs to Solve Single-Cell Reasoning Puzzles with Reinforcement Learning*. ArXiv:2506.02911. [https://www.semanticscholar.org/paper/5f145bd0636027e192d7c8d0102806166fc30d64](https://www.semanticscholar.org/paper/5f145bd0636027e192d7c8d0102806166fc30d64)
28. Kai Lan, Jiayong Zhu, Jiangtong Li, Dawei Cheng, Guang Chen, Changjun Jiang (2025). *FinLMM-R1: Enhancing Financial Reasoning in LMM through Scalable Data and Reward Design*. ArXiv:2506.13066. [https://www.semanticscholar.org/paper/3c27f1433f893bf8071bd0e0a6d8ac5a860d81ee](https://www.semanticscholar.org/paper/3c27f1433f893bf8071bd0e0a6d8ac5a860d81ee)
29. Yichun Feng, Jiawei Wang, Lu Zhou, Yixue Li (2025). *DoctorAgent-RL: A Multi-Agent Collaborative Reinforcement Learning System for Multi-Turn Clinical Dialogue*. ArXiv:2505.19630. [https://www.semanticscholar.org/paper/8f2eef2e8df6d9e1bc9b73df30fe7956c27faeb4](https://www.semanticscholar.org/paper/8f2eef2e8df6d9e1bc9b73df30fe7956c27faeb4)
30. Wei Dai, Peilin Chen, Chanakya Ekbote, Paul Pu Liang (2025). *QoQ-Med: Building Multimodal Clinical Foundation Models with Domain-Aware GRPO Training*. ArXiv:2506.00711v1. [https://arxiv.org/pdf/2506.00711v1](https://arxiv.org/pdf/2506.00711v1)
31. Khaled Saab, Jan Freyberg, Chunjong Park, Tim Strother, Yong Cheng, Wei-Hung Weng, David G. T. Barrett, David Stutz, Nenad Tomasev, Anil Palepu, Valentin Liévin, Yash Sharma, Roma Ruparel, Abdullah Ahmed, Elahe Vedadi, Kimberly Kanada, Cian Hughes, Yun Liu, Geoff Brown, Yang Gao, Sean Li, S. Sara Mahdavi, James Manyika, Katherine Chou, Yossi Matias, Avinatan Hassidim, Dale R. Webster, Pushmeet Kohli, S. M. Ali Eslami, Joëlle Barral, Adam Rodman, Vivek Natarajan, Mike Schaekermann, Tao Tu, Alan Karthikesalingam, Ryutaro Tanno (2025). *Advancing Conversational Diagnostic AI with Multimodal Reasoning*. ArXiv:2505.04653v1. [https://arxiv.org/pdf/2505.04653v1](https://arxiv.org/pdf/2505.04653v1)
32. Honglong Yang, Shanshan Song, Yi Qin, Lehan Wang, Haonan Wang, Xinpeng Ding, Qixiang Zhang, Bodong Du, Xiaomeng Li (2025). *Multi-Modal Explainable Medical AI Assistant for Trustworthy Human-AI Collaboration*. ArXiv:2505.06898. [https://www.semanticscholar.org/paper/07d266beef338141705430cce2bdd8419ca90250](https://www.semanticscholar.org/paper/07d266beef338141705430cce2bdd8419ca90250)
33. Shuang Zhou, Jiashuo Wang, Zidu Xu, Song Wang, David Brauer, Lindsay Welton, Jacob C. Cogan, Yuen-Hei Chung, Lei Tian, Zaifu Zhan, Yu Hou, Mingquan Lin, Genevieve B. Melton, Rui Zhang (2025). *Uncertainty-Aware Large Language Models for Explainable Disease Diagnosis*. ArXiv:2505.03467. [https://www.semanticscholar.org/paper/099538285ce1f8e42fbed3e108a530c8673e03cd](https://www.semanticscholar.org/paper/099538285ce1f8e42fbed3e108a530c8673e03cd)
34. Amit Kumthekar, Zion Tilley, Henry Duong, Bhargav Patel, Michael Magnoli, Ahmed Omar, Ahmed Nasser, Chaitanya Gharpure, Yevgen Reztzov (2025). *Second Opinion Matters: Towards Adaptive Clinical AI via the Consensus of Expert Model Ensemble*. ArXiv:2505.23075. [https://www.semanticscholar.org/paper/b7aba93de3fe63f59c7f567d61e72cabbc47b369](https://www.semanticscholar.org/paper/b7aba93de3fe63f59c7f567d61e72cabbc47b369)
35. Meng Xiao, Xunxin Cai, Chengrui Wang, Yuanchun Zhou (2025). *m-KAILIN: Knowledge-Driven Agentic Scientific Corpus Distillation Framework for Biomedical Large Language Models Training*. ArXiv:10.48550/arXiv.2504.19565. [https://www.semanticscholar.org/paper/519d0d11f208d6f9d6b1f159d25e192e04f0effe](https://www.semanticscholar.org/paper/519d0d11f208d6f9d6b1f159d25e192e04f0effe)
36. Haoyang Li, Jie Xu, Kyra Gan, Fei Wang, Chengxi Zang (2025). *Federated Causal Inference in Healthcare: Methods, Challenges, and Applications*. ArXiv:2505.02238v1. [https://arxiv.org/pdf/2505.02238v1](https://arxiv.org/pdf/2505.02238v1)
37. Khellaf R'emi, Bellet Aur'elien, Josse Julie (2025). *Federated Causal Inference from Multi-Site Observational Data via Propensity Score Aggregation*. ArXiv:2505.17961. [https://www.semanticscholar.org/paper/f41bf8196886d56c9614c826602b72968500ae30](https://www.semanticscholar.org/paper/f41bf8196886d56c9614c826602b72968500ae30)
38. C. Lebeda, Mathieu Even, A. Bellet, Julie Josse (2025). *Model Agnostic Differentially Private Causal Inference*. ArXiv:2505.19589. [https://www.semanticscholar.org/paper/9f12534ea97cc150ca71362b3682aba0318cf526](https://www.semanticscholar.org/paper/9f12534ea97cc150ca71362b3682aba0318cf526)
39. Winston Chen, Trenton Chang, Jenna Wiens (2025). *Conditional Front-door Adjustment for Heterogeneous Treatment Assignment Effect Estimation Under Non-adherence*. ArXiv:2505.05677v1. [https://arxiv.org/pdf/2505.05677v1](https://arxiv.org/pdf/2505.05677v1)
40. Yingrong Wang, Anpeng Wu, Baohong Li, Ziyang Xiao, Ruoxuan Xiong, Qing Han, Kun Kuang (2025). *Sequential Treatment Effect Estimation with Unmeasured Confounders*. ArXiv:2505.09113v1. [https://arxiv.org/pdf/2505.09113v1](https://arxiv.org/pdf/2505.09113v1)
41. Ruichu Cai, Junjie Wan, Weilin Chen, Zeqin Yang, Zijian Li, Peng Zhen, Jiecheng Guo (2025). *Long-Term Individual Causal Effect Estimation via Identifiable Latent Representation Learning*. ArXiv:2505.05192. [https://www.semanticscholar.org/paper/8db7c516535310183746fade7a6c68874b43cb80](https://www.semanticscholar.org/paper/8db7c516535310183746fade7a6c68874b43cb80)
42. Ahmed Aloui, Juncheng Dong, Ali Hasan, Vahid Tarokh (2025). *Conditional Average Treatment Effect Estimation Under Hidden Confounders*. ArXiv:2506.12304. [https://www.semanticscholar.org/paper/640e7f89c751c463cbb60b763c24d4c4e51e2564](https://www.semanticscholar.org/paper/640e7f89c751c463cbb60b763c24d4c4e51e2564)
43. H. C. Kottler, Amy Cochran (2025). *A simplified and robust proxy-based approach for overcoming unmeasured confounding in EHR studies*. ArXiv:2506.12177. [https://www.semanticscholar.org/paper/841046da73e7b2bb4eb2b4cb370ed26e49e4a808](https://www.semanticscholar.org/paper/841046da73e7b2bb4eb2b4cb370ed26e49e4a808)
44. Myeonghun Yu, Xu Shi, E. T. Tchetgen (2025). *Fortified Proximal Causal Inference with Many Invalid Proxies*. ArXiv:2506.13152. [https://www.semanticscholar.org/paper/51d1422c9ed0148da712a1af8334b66d5446ebf2](https://www.semanticscholar.org/paper/51d1422c9ed0148da712a1af8334b66d5446ebf2)
45. Ayoub Abraich (2025). *TV-SurvCaus: Dynamic Representation Balancing for Causal Survival Analysis*. ArXiv:2505.01785v1. [https://arxiv.org/pdf/2505.01785v1](https://arxiv.org/pdf/2505.01785v1)
46. Dennis Frauen, Maresa Schroder, Konstantin Hess, Stefan Feuerriegel (2025). *Orthogonal Survival Learners for Estimating Heterogeneous Treatment Effects from Time-to-Event Data*. ArXiv:2505.13072. [https://www.semanticscholar.org/paper/274bbf387692673fb1fee244330e02afabaa8218](https://www.semanticscholar.org/paper/274bbf387692673fb1fee244330e02afabaa8218)
47. S. Kalia, Olli Saarela, Tao Chen, Braden O'Neill, C. Meaney, Rahim Moineddin, B. Aliarzadeh, Frank Sullivan, Michelle Greiver (2025). *Continuous‐Time Causal Inference With Marked Point Process Weights: An Example on Sodium‐Glucose Co‐Transporters 2 Inhibitor Medications and Urinary Tract Infection*. ArXiv:10.1002/sim.70102. [https://www.semanticscholar.org/paper/a2d764b6ffba33df9ab263dcc7ac02a35ef7a740](https://www.semanticscholar.org/paper/a2d764b6ffba33df9ab263dcc7ac02a35ef7a740)
48. Sumyyah Toonsi, Paul Schofield, Robert Hoehndorf (2025). *Causal knowledge graph analysis identifies adverse drug effects*. ArXiv:2505.06949v1. [https://arxiv.org/pdf/2505.06949v1](https://arxiv.org/pdf/2505.06949v1)
49. Roger Pros, Jordi Vitrià (2025). *Preventing Spurious Interactions: A New Inductive Bias for Accurate Treatment Effect Estimation*. ArXiv:10.1109/ACCESS.2025.3574547. [https://www.semanticscholar.org/paper/09bca14c37c1ca78416406d3d11e80080429bd89](https://www.semanticscholar.org/paper/09bca14c37c1ca78416406d3d11e80080429bd89)
50. Praharsh Nanavati, Ranjitha Prasad, Karthikeyan Shanmugam (2025). *Representation Learning Preserving Ignorability and Covariate Matching for Treatment Effects*. ArXiv:10.48550/arXiv.2504.20579. [https://www.semanticscholar.org/paper/77b99b31f318edf64110a1ce3d8bd3db82dc2b3b](https://www.semanticscholar.org/paper/77b99b31f318edf64110a1ce3d8bd3db82dc2b3b)
51. Ahmed Sayeed Faruk, Jason Sulskis, Elena Zheleva (2025). *Estimating Causal Effects in Networks with Cluster-Based Bandits*. ArXiv:2505.04200v1. [https://arxiv.org/pdf/2505.04200v1](https://arxiv.org/pdf/2505.04200v1)
52. Sofia Ek, Dave Zachariah (2025). *Learning Treatment Allocations with Risk Control Under Partial Identifiability*. ArXiv:2505.08378v1. [https://arxiv.org/pdf/2505.08378v1](https://arxiv.org/pdf/2505.08378v1)
53. M. Oprescu, Brian M Cho, Nathan Kallus (2025). *Efficient Adaptive Experimentation with Non-Compliance*. ArXiv:2505.17468. [https://www.semanticscholar.org/paper/353ffa37167c1a43487faa766fd2c644d118db2](https://www.semanticscholar.org/paper/353ffa37167c1a43487faa766fd2c644d118db2)
54. Prateek Jaiswal, Esmaeil Keyvanshokooh, Junyu Cao (2025). *Deconfounded Warm-Start Thompson Sampling with Applications to Precision Medicine*. ArXiv:2505.17283. [https://www.semanticscholar.org/paper/ff505d99d2fb1673f1a41dfe26deeb573ef1a600](https://www.semanticscholar.org/paper/ff505d99d2fb1673f1a41dfe26deeb573ef1a600)
55. Undral Byambadalai, Tomu Hirata, Tatsushi Oka, Shota Yasui (2025). *On Efficient Estimation of Distributional Treatment Effects under Covariate-Adaptive Randomization*. ArXiv:2506.05945. [https://www.semanticscholar.org/paper/c8e1a0efae9b7e7ffe6774205ba90941e7d70467](https://www.semanticscholar.org/paper/c8e1a0efae9b7e7ffe6774205ba90941e7d70467)
56. Quinn Lanners, Cynthia Rudin, A. Volfovsky, Harsh Parikh (2025). *Data Fusion for Partial Identification of Causal Effects*. ArXiv:2505.24296. [https://www.semanticscholar.org/paper/ab1cdc803561f79fd5303265c6f289ed40f19b1d](https://www.semanticscholar.org/paper/ab1cdc803561f79fd5303265c6f289ed40f19b1d)
57. Yuchen Ma, Jonas Schweisthal, Hengrui Zhang, Stefan Feuerriegel (2025). *A Diffusion-Based Method for Learning the Multi-Outcome Distribution of Medical Treatments*. ArXiv:2506.01533. [https://www.semanticscholar.org/paper/7e821ab0513faf7425663e5d769d5a2cf2130367](https://www.semanticscholar.org/paper/7e821ab0513faf7425663e5d769d5a2cf2130367)
58. Qingyan Xiang, Yubai Yuan, Dongyuan Song, Usman J Wudil, Muktar H Aliyu, C. W. Wester, Bryan E. Shepherd (2025). *Double machine learning to estimate the effects of multiple treatments and their interactions*. ArXiv:2505.12617. [https://www.semanticscholar.org/paper/2dd809014f676593615976e1dc0182b3120b4ca5](https://www.semanticscholar.org/paper/2dd809014f676593615976e1dc0182b3120b4ca5)
59. Jake Robertson, Arik Reuter, Siyuan Guo, Noah Hollmann, Frank Hutter, Bernhard Scholkopf (2025). *Do-PFN: In-Context Learning for Causal Effect Estimation*. ArXiv:2506.06039. [https://www.semanticscholar.org/paper/22de6bbc648fd723db7c12bb2ad7d9d95e70b7c0](https://www.semanticscholar.org/paper/22de6bbc648fd723db7c12bb2ad7d9d95e70b7c0)
60. Vahid Balazadeh, Hamidreza Kamkari, Valentin Thomas, Benson Li, Junwei Ma, Jesse C. Cresswell, Rahul G. Krishnan (2025). *CausalPFN: Amortized Causal Effect Estimation via In-Context Learning*. ArXiv:2506.07918. [https://www.semanticscholar.org/paper/55586284afcecbd4e86f2a96b957be315a819b00](https://www.semanticscholar.org/paper/55586284afcecbd4e86f2a96b957be315a819b00)
61. Alexandre Cotorobai, Jorge Miguel Silva, Jose Luis Oliveira (2025). *A Federated Random Forest Solution for Secure Distributed Machine Learning*. ArXiv:2505.08085v1. [https://arxiv.org/pdf/2505.08085v1](https://arxiv.org/pdf/2505.08085v1)
62. Anum Nawaz, Muhammad Irfan, Xianjia Yu, Zhuo Zou, Tomi Westerlund (2025). *Blockchain-Enabled Privacy-Preserving Second-Order Federated Edge Learning in Personalized Healthcare*. ArXiv:2506.00416v1. [https://arxiv.org/pdf/2506.00416v1](https://arxiv.org/pdf/2506.00416v1)
63. S. Hafeez, S. R. Mulkana, Muhammad Ali Imran, Michele Sevegnani (2025). *Federated Deep Reinforcement Learning for Privacy-Preserving Robotic-Assisted Surgery*. ArXiv:2505.12153. [https://www.semanticscholar.org/paper/99989716d3e8743e9e6b6f94f1eaec4a0d76c08a](https://www.semanticscholar.org/paper/99989716d3e8743e9e6b6f94f1eaec4a0d76c08a)
64. Mohammad Nasajpour, Seyedamin Pouriyeh, R. Parizi, Meng Han, Fatemeh Mosaiyebzadeh, Yixin Xie, Liyuan Liu, Daniel M. Batista (2025). *Advances in Application of Federated Machine Learning for Oncology and Cancer Diagnosis*. ArXiv:10.3390/info16060487. [https://www.semanticscholar.org/paper/a1c3ebc807648c068b446870e1b0748cf2a3a96b](https://www.semanticscholar.org/paper/a1c3ebc807648c068b446870e1b0748cf2a3a96b)
65. P. U. Shankar, E. S. Rahul, K. D. Rao, K. Satish, U. D. Kumar, D. Ravindra, G. Subbarao (2025). *Liver Disease Prediction using Federated Learning*. ArXiv:10.38124/ijisrt/25apr626. [https://www.semanticscholar.org/paper/f0647f9b2cedba95500bb472dd1a1359ac737819](https://www.semanticscholar.org/paper/f0647f9b2cedba95500bb472dd1a1359ac737819)
66. Tariq Sa'ad Jarrar, A. Hudaib, Nadim Obeid (2025). *Investigating the Utilization of Federated Learning to Enhance Diabetes Predictions*. ArXiv:10.1109/ICCIAA65327.2025.11013686. [https://www.semanticscholar.org/paper/2925179a6fb06afa9e4f3402124ae4d9a146daf5](https://www.semanticscholar.org/paper/2925179a6fb06afa9e4f3402124ae4d9a146daf5)
67. Qiming Wu, Siqi Li, Doudou Zhou, Nan Liu (2025). *Toward Fair Federated Learning under Demographic Disparities and Data Imbalance*. ArXiv:2505.09295v1. [https://arxiv.org/pdf/2505.09295v1](https://arxiv.org/pdf/2505.09295v1)
68. Alpaslan Gokcen, Ali Boyacı (2025). *Robust Federated Learning with Confidence-Weighted Filtering and GAN-Based Completion under Noisy and Incomplete Data*. ArXiv:2505.09733. [https://www.semanticscholar.org/paper/ccc8216359874d5c2b2112a7f0feddbb40e4a1e6](https://www.semanticscholar.org/paper/ccc8216359874d5c2b2112a7f0feddbb40e4a1e6)
69. Kitsuya Azuma, Takayuki Nishio, Yuichi Kitagawa, Wakako Nakano, Takahito Tanimura (2025). *Soft-Label Caching and Sharpening for Communication-Efficient Federated Distillation*. ArXiv:10.48550/arXiv.2504.19602. [https://www.semanticscholar.org/paper/6e2ee56c63f69cb94ecec92333f378461dc56bf1](https://www.semanticscholar.org/paper/6e2ee56c63f69cb94ecec92333f378461dc56bf1)
70. Gaurav Goel, Anil Kumar Pandey, Dinesh Kumar Singh, Shobhit Sinha (2025). *Federated Adaptive Personalized Optimization (Fed-APO): A Meta-Learning Approach to Enhancing Healthcare for Non-IID Multi-Healthcare Data*. ArXiv:10.22399/ijcesen.1646. [https://www.semanticscholar.org/paper/201be4e27b0169c1c52dabef8bff2e23b39f824c](https://www.semanticscholar.org/paper/201be4e27b0169c1c52dabef8bff2e23b39f824c)
71. Jieming Bian, Yuanzhe Peng, Lei Wang, Yingyu Huang, Jie Xu (2025). *A Survey on Parameter-Efficient Fine-Tuning for Foundation Models in Federated Learning*. ArXiv:10.48550/arXiv.2504.21099. [https://www.semanticscholar.org/paper/9c381e4cd9234546c5c95fdd9fe328ff78d42d42](https://www.semanticscholar.org/paper/9c381e4cd9234546c5c95fdd9fe328ff78d42d42)
72. Qianren Mao, Qili Zhang, Hanwen Hao, Zhen-Hui Han, Runhua Xu, Weifeng Jiang, Qi Hu, Zhijun Chen, Tyler Zhou, Bo Li, Yangqiu Song, Jin Dong, Jianxin Li, Philip S. Yu (2025). *Privacy-Preserving Federated Embedding Learning for Localized Retrieval-Augmented Generation*. ArXiv:10.48550/arXiv.2504.19101. [https://www.semanticscholar.org/paper/4eb4edc7d0bea4216b1004c6605dd4f8850b69ed](https://www.semanticscholar.org/paper/4eb4edc7d0bea4216b1004c6605dd4f8850b69ed)
73. Santhosh Parampottupadam, Melih Cocsugun, Sarthak Pati, M. Zenk, Saikat Roy, Dimitrios Bounias, Benjamin Hamm, Sinem Sav, Ralf Floca, K. Maier-Hein (2025). *Inclusive, Differentially Private Federated Learning for Clinical Data*. ArXiv:2505.22108. [https://www.semanticscholar.org/paper/ffe322720ec348e0501b42a63b0fe00fb5d10c36](https://www.semanticscholar.org/paper/ffe322720ec348e0501b42a63b0fe00fb5d10c36)
74. Flora Amato, Lingyu Qiu, Mohammad Tanveer, Salvatore Cuomo, F. Giampaolo, Francesco Piccialli (2025). *Towards One-shot Federated Learning: Advances, Challenges, and Future Directions*. ArXiv:10.48550/arXiv.2505.02426. [https://www.semanticscholar.org/paper/0e0a2db55884f82de43b3741cfd28ed53942eca6](https://www.semanticscholar.org/paper/0e0a2db55884f82de43b3741cfd28ed53942eca6)
75. Waldemar Hahn, Jan-Niklas Eckardt, Christoph Röllig, Martin Sedlmayr, Jan Moritz Middeke, Markus Wolfien (2025). *Generating Reliable Synthetic Clinical Trial Data: The Role of Hyperparameter Optimization and Domain Constraints*. ArXiv:2505.05019v1. [https://arxiv.org/pdf/2505.05019v1](https://arxiv.org/pdf/2505.05019v1)
76. Saritha Kondapally (2025). *BALANCING PRIVACY AND INNOVATION A VAE FRAMEWORK AOR SYNTHETIC HEALTHCARE DATA GENERATION*. ArXiv:10.5121/ijaia.2025.16302. [https://www.semanticscholar.org/paper/c701997be98f702f3ea57c1f4ec7d1cd14fff725](https://www.semanticscholar.org/paper/c701997be98f702f3ea57c1f4ec7d1cd14fff725)
77. Ziyu Li, Yujian Hu, Zhengyao Ding, Yiheng Mao, Haitao Li, Fan Yi, Hongkun Zhang, Zhengxing Huang (2025). *Phenotype-Guided Generative Model for High-Fidelity Cardiac MRI Synthesis: Advancing Pretraining and Clinical Applications*. ArXiv:2505.03426v1. [https://arxiv.org/pdf/2505.03426v1](https://arxiv.org/pdf/2505.03426v1)
78. Ruxue Shi, Yili Wang, Mengnan Du, Xu Shen, Xin Wang (2025). *A Comprehensive Survey of Synthetic Tabular Data Generation*. ArXiv:10.48550/arXiv.2504.16506. [https://www.semanticscholar.org/paper/62623220ebe64c1ae134c51b73a1ab37667761d5](https://www.semanticscholar.org/paper/62623220ebe64c1ae134c51b73a1ab37667761d5)
79. Larissa Montenegro, Luis M. Gomes, José Machado (2025). *What We Know About the Role of Large Language Models for Medical Synthetic Dataset Generation*. ArXiv:10.3390/ai6060109. [https://www.semanticscholar.org/paper/9efdd09bb8c967052f7e035f45f4e41fad79c7d0](https://www.semanticscholar.org/paper/9efdd09bb8c967052f7e035f45f4e41fad79c7d0)
80. Yuanyuan Zhang, Xinfeng Zhang, Xiaoming Qi, Xinyu Wu, Feng Chen, Guanyu Yang, Huazhu Fu (2025). *Generative Models in Computational Pathology: A Comprehensive Survey on Methods, Applications, and Challenges*. ArXiv:2505.10993. [https://www.semanticscholar.org/paper/6db9ce714320621672909dc286755cb11cc6f7e4](https://www.semanticscholar.org/paper/6db9ce714320621672909dc286755cb11cc6f7e4)
81. Bradley Max Segal, Joshua Fieggen, David A. Clifton, Lei A. Clifton (2025). *Bridging the Generalisation Gap: Synthetic Data Generation for Multi-Site Clinical Model Validation*. ArXiv:10.48550/arXiv.2504.20635. [https://www.semanticscholar.org/paper/8315d25e966cb77783da5d43e2aee3fcd9bf58ad](https://www.semanticscholar.org/paper/8315d25e966cb77783da5d43e2aee3fcd9bf58ad)
82. Khadija Benjilali, Abdeljalil El-Ibrahimi, Wassima Moutaouakil, S. Hamida, B. Cherradi, Omar Bouattane (2025). *AI-Driven Generative Modeling and Optimization for Ethical and Scalable Selection Systems: A Multi-Domain Scoping Review*. ArXiv:10.1109/IRASET64571.2025.11008162. [https://www.semanticscholar.org/paper/7483d3a018915ef891896e2a8e1fcfe441f2143f](https://www.semanticscholar.org/paper/7483d3a018915ef891896e2a8e1fcfe441f2143f)
83. L. Julián Lechuga López, Shaza Elsharief, Dhiyaa Al Jorf, Firas Darwish, Congbo Ma, Farah E. Shamout (2025). *Uncertainty Quantification for Machine Learning in Healthcare: A Survey*. ArXiv:2505.02874v1. [https://arxiv.org/pdf/2505.02874v1](https://arxiv.org/pdf/2505.02874v1)
84. Suhas BN, Han-Chin Shing, Lei Xu, Mitch Strong, Jon Burnsky, Jessica Ofor, Jordan R. Mason, Susan Chen, Sundararajan Srinivasan, Chaitanya Shivade, Jack Moriarty, Joseph Paul Cohen (2025). *Fact-Controlled Diagnosis of Hallucinations in Medical Text Summarization*. ArXiv:2506.00448v1. [https://arxiv.org/pdf/2506.00448v1](https://arxiv.org/pdf/2506.00448v1)
85. Yifan Wei, Xiaoyan Yu, Tengfei Pan, Angsheng Li, Li Du (2025). *Structural Entropy Guided Agent for Detecting and Repairing Knowledge Deficiencies in LLMs*. ArXiv:2505.07184v1. [https://arxiv.org/pdf/2505.07184v1](https://arxiv.org/pdf/2505.07184v1)
86. Faisal Abdullah, Althobaiti (2025). *A Survey on Using Large Language Models in Healthcare*. ArXiv:10.7753/ijsea1406.1001. [https://www.semanticscholar.org/paper/a4730fd88d2249de1bed9a0f1a9a7641b1caba8d](https://www.semanticscholar.org/paper/a4730fd88d2249de1bed9a0f1a9a7641b1caba8d)
87. Krunal Wankhade, Devesh Jain, Sakshi Suryavanshi (2025). *Developing Interpretable Large Language Models for High-Stakes Decision-Making in Healthcare: Insights from an XAI Review Perspective*. ArXiv:10.55248/gengpi.6.0525.1615. [https://www.semanticscholar.org/paper/12115434fdfa47869ea6f3c24c5bd82ba99ced65](https://www.semanticscholar.org/paper/12115434fdfa47869ea6f3c24c5bd82ba99ced65)
88. Muskan Garg, Shaina Raza, Shebuti Rayana, Xingyi Liu, Sunghwan Sohn (2025). *The Rise of Small Language Models in Healthcare: A Comprehensive Survey*. ArXiv:10.48550/arXiv.2504.17119. [https://www.semanticscholar.org/paper/d0e6b0a43edec2424005ee900c6d657597bd7d16](https://www.semanticscholar.org/paper/d0e6b0a43edec2424005ee900c6d657597bd7d16)
89. Chengzhang Yu, Yiming Zhang, Zhixin Liu, Zenghui Ding, Yining Sun, Zhanpeng Jin (2025). *FRAME: Feedback-Refined Agent Methodology for Enhancing Medical Research Insights*. ArXiv:2505.04649v1. [https://arxiv.org/pdf/2505.04649v1](https://arxiv.org/pdf/2505.04649v1)
90. Shuai Wang, Harrisen Scells, Bevan Koopman, Guido Zuccon (2025). *Reassessing Large Language Model Boolean Query Generation for Systematic Reviews*. ArXiv:2505.07155v2. [https://arxiv.org/pdf/2505.07155v2](https://arxiv.org/pdf/2505.07155v2)
91. Joao Torres, Catherine Mulligan, Joaquim A. Jorge, Catarina Moreira (2025). *PROMPTHEUS: A Human-Centered Pipeline to Streamline Systematic Literature Reviews with Large Language Models*. ArXiv:10.3390/info16050420. [https://www.semanticscholar.org/paper/b81dcd32fbf9bcef7a5314cf94466251dd3b7d3e](https://www.semanticscholar.org/paper/b81dcd32fbf9bcef7a5314cf94466251dd3b7d3e)
92. Pierre Achkar, Tim Gollub, Martin Potthast (2025). *Ask, Retrieve, Summarize: A Modular Pipeline for Scientific Literature Summarization*. ArXiv:2505.16349. [https://www.semanticscholar.org/paper/088381cf6f58cbf7b4ebac4086c32c778b4a4877](https://www.semanticscholar.org/paper/088381cf6f58cbf7b4ebac4086c32c778b4a4877)
93. Xiao Wang, Mengjue Tan, Qiao Jin, Guangzhi Xiong, Yu Hu, Aidong Zhang, Zhiyong Lu, Minjia Zhang (2025). *MedCite: Can Language Models Generate Verifiable Text for Medicine?*. ArXiv:2506.06605. [https://www.semanticscholar.org/paper/4082c099c95320a1938fda1e4bc195e30b45c6d2](https://www.semanticscholar.org/paper/4082c099c95320a1938fda1e4bc195e30b45c6d2)
94. Brice Edelman, Jeffrey Skolnick (2025). *Valsci: an open-source, self-hostable literature review utility for automated large-batch scientific claim verification using large language models*. ArXiv:10.1186/s12859-025-06159-4. [https://www.semanticscholar.org/paper/13e079da1dba19509dfd1fd05440b1a52666603a](https://www.semanticscholar.org/paper/13e079da1dba19509dfd1fd05440b1a52666603a)
95. Massimiliano Pronesti, Joao Bettencourt-Silva, Paul Flanagan, Alessandra Pascale, Oisin Redmond, Anya Belz, Yufang Hou (2025). *Query-driven Document-level Scientific Evidence Extraction from Biomedical Studies*. ArXiv:2505.06186v1. [https://arxiv.org/pdf/2505.06186v1](https://arxiv.org/pdf/2505.06186v1)
96. L. M. Amugongo, Pietro Mascheroni, Steven Brooks, Stefan Doering, Jan Seidel (2025). *Retrieval augmented generation for large language models in healthcare: A systematic review*. ArXiv:10.1371/journal.pdig.0000877. [https://www.semanticscholar.org/paper/5879575701b9b65b5cc56c00d9eebbfa219e0428](https://www.semanticscholar.org/paper/5879575701b9b65b5cc56c00d9eebbfa219e0428)
97. Adel Ammar, Anis Koubaa, Omer Nacar, Wadii Boulila (2025). *Optimizing Retrieval-Augmented Generation: Analysis of Hyperparameter Impact on Performance and Efficiency*. ArXiv:2505.08445v1. [https://arxiv.org/pdf/2505.08445v1](https://arxiv.org/pdf/2505.08445v1)
98. Carlo Merola, Jaspinder Singh (2025). *Reconstructing Context: Evaluating Advanced Chunking Strategies for Retrieval-Augmented Generation*. ArXiv:10.48550/arXiv.2504.19754. [https://www.semanticscholar.org/paper/ecaa4c26cebc4d53e1712c2ab2a2c82e3861b9b1](https://www.semanticscholar.org/paper/ecaa4c26cebc4d53e1712c2ab2a2c82e3861b9b1)
99. Fahmida Liza Piya, Rahmatollah Beheshti (2025). *ConTextual: Improving Clinical Text Summarization in LLMs with Context-preserving Token Filtering and Knowledge Graphs*. ArXiv:10.48550/arXiv.2504.16394. [https://www.semanticscholar.org/paper/36bf667b489fc59ef684913a5f535f4949ca7584](https://www.semanticscholar.org/paper/36bf667b489fc59ef684913a5f535f4949ca7584)
100. S. Mohammed, J. Fiaidhi, T. Sekar, K. Kushal, S. Shankar (2025). *Investigations on using Evidence-Based GraphRag Pipeline using LLM Tailored for Answering USMLE Medical Exam Questions*. ArXiv:10.1101/2025.05.03.25325604. [https://www.semanticscholar.org/paper/573721af3692834841c3e82303a3bfabb98423b9](https://www.semanticscholar.org/paper/573721af3692834841c3e82303a3bfabb98423b9)
101. Dario Garcia-Gasulla, Jordi Bayarri-Planas, Ashwin Kumar Gururajan, Enrique Lopez-Cuena, Adrian Tormos, Daniel Hinjos, Pablo Bernabeu-Perez, Anna Arias-Duart, Pablo Agustin Martin-Torres, Marta Gonzalez-Mallo, Sergio Alvarez-Napagao, Eduard Ayguadé-Parra, Ulises Cortés (2025). *The Aloe Family Recipe for Open and Specialized Healthcare LLMs*. ArXiv:2505.04388v1. [https://arxiv.org/pdf/2505.04388v1](https://arxiv.org/pdf/2505.04388v1)
102. Jiawei He, Boya Zhang, H. Rouhizadeh, Yingjian Chen, Rui Yang, Jin Lu, Xudong Chen, Nan Liu, Irene Li, Douglas Teodoro (2025). *Retrieval-Augmented Generation in Biomedicine: A Survey of Technologies, Datasets, and Clinical Applications*. ArXiv:2505.01146. [https://www.semanticscholar.org/paper/ea2f72b979e2646dec92a9ce9b6b07dd0a20e789](https://www.semanticscholar.org/paper/ea2f72b979e2646dec92a9ce9b6b07dd0a20e789)
103. Mario Ceresa, Lorenzo Bertolini, Valentin Comte, Nicholas Spadaro, B. Raffael, Brigitte Toussaint, Sergio Consoli, Amalia Munoz Pineiro, Alex Patak, M. Querci, Tobias Wiesenthal (2025). *Retrieval Augmented Generation Evaluation for Health Documents*. ArXiv:2505.04680. [https://www.semanticscholar.org/paper/78452726f73fa58e22391cc8b3b7819f38fc24bf](https://www.semanticscholar.org/paper/78452726f73fa58e22391cc8b3b7819f38fc24bf)
104. Sofia Jamil, Aryan Dabad, Bollampalli Areen Reddy, Sriparna Saha, Rajiv Misra, Adil A. Shakur (2025). *GASCADE: Grouped Summarization of Adverse Drug Event for Enhanced Cancer Pharmacovigilance*. ArXiv:2505.04284v1. [https://arxiv.org/pdf/2505.04284v1](https://arxiv.org/pdf/2505.04284v1)
105. Qinyue Zheng, Salman Abdullah, Sam Rawal, Cyril Zakka, Sophie Ostmeier, Maximilian Purk, Eduardo Reis, E.J. Topol, J. Leskovec, Michael Moor (2025). *MIRIAD: Augmenting LLMs with millions of medical query-response pairs*. ArXiv:2506.06091. [https://www.semanticscholar.org/paper/b1afad9875b76d2746c9c1bcad2c693110920987](https://www.semanticscholar.org/paper/b1afad9875b76d2746c9c1bcad2c693110920987)
106. Lorenz Brehme, Thomas Ströhle, Ruth Breu (2025). *Can LLMs Be Trusted for Evaluating RAG Systems? A Survey of Methods and Datasets*. ArXiv:10.48550/arXiv.2504.20119. [https://www.semanticscholar.org/paper/1cdbb922dcc977100e381a5debedb37994d27363](https://www.semanticscholar.org/paper/1cdbb922dcc977100e381a5debedb37994d27363)
107. Lo Pang-Yun Ting, Hong-Pei Chen, An-Shan Liu, Chun-Yin Yeh, Po-Lin Chen, Kun-Ta Chuang (2025). *Early Detection of Patient Deterioration from Real-Time Wearable Monitoring System*. ArXiv:2505.01305v1. [https://arxiv.org/pdf/2505.01305v1](https://arxiv.org/pdf/2505.01305v1)
108. Yi Wang, Weihua Li (2025). *Integrating Multimodal EHR Data for Mortality Prediction in ICU Sepsis Patients*. ArXiv:10.1002/sim.70060. [https://www.semanticscholar.org/paper/b847ce14966bdb9af77501f0850f45b4411f85e0](https://www.semanticscholar.org/paper/b847ce14966bdb9af77501f0850f45b4411f85e0)
109. M. C. Sekhar, Pasam Naga Kavitha, B.N.V. Uma Shankar, Amrutavalli Aakula, Divya Boya (2025). *MedFusionAI: A Deep Learning Framework for Multi-Modal Health Data Fusion to Predict Chronic Disease Risks*. ArXiv:10.22399/ijcesen.2159. [https://www.semanticscholar.org/paper/0b58e33e5512543ac6fb3c30644ae8b3a54d76c0](https://www.semanticscholar.org/paper/0b58e33e5512543ac6fb3c30644ae8b3a54d76c0)
110. Shaojie Zhong, Li Rong Wang, Zhuoxuan Zhan, Y. Ng, Xiuyi Fan (2025). *A Hybrid Approach for Irregular-Time Series Prediction using Electronic Health Records: an Intensive Care Unit Mortality Case Study*. ArXiv:10.1145/3743689. [https://www.semanticscholar.org/paper/58cd1dc7c95a9d367b822b5e533728b5e25e6bff](https://www.semanticscholar.org/paper/58cd1dc7c95a9d367b822b5e533728b5e25e6bff)
111. A. Septiandri, Deyu Ming, F. DiazDelaO, T. Jendoubi, Samiran Ray (2025). *Integrative Analysis and Imputation of Multiple Data Streams via Deep Gaussian Processes*. ArXiv:2505.12076. [https://www.semanticscholar.org/paper/628c0d3d185606195ca1dcb8758ede3621dbe1f7](https://www.semanticscholar.org/paper/628c0d3d185606195ca1dcb8758ede3621dbe1f7)
112. Andrea Zerio, Maya Bechler-Speicher, Maor Huri, M. V. Vestergaard, Ran Gilad-Bachrach, Tine Jess, Samir Bhatt, A. Sazonovs (2025). *Interpretable Graph Learning Over Sets of Temporally-Sparse Data*. ArXiv:2505.19193. [https://www.semanticscholar.org/paper/ecb0c71c3ff63fa2f706df9079f5e8f144e90955](https://www.semanticscholar.org/paper/ecb0c71c3ff63fa2f706df9079f5e8f144e90955)
113. Hao Li, Bowen Deng, Chang Xu, Zhiyuan Feng, Viktor Schlegel, Yu-Hao Huang, Yizheng Sun, Jingyuan Sun, Kailai Yang, Yiyao Yu, Jiang Bian (2025). *MIRA: Medical Time Series Foundation Model for Real-World Health Data*. ArXiv:2506.07584. [https://www.semanticscholar.org/paper/d64d108fd7fae6535543de8029bc0e40a02526ea](https://www.semanticscholar.org/paper/d64d108fd7fae6535543de8029bc0e40a02526ea)
114. Farhana Yeasmin, Shamsul Arefeen, Rafi Muhammad Zakaria, Abid Hasan (2025). *Predictive Modeling of Patient Health Outcomes Using Electronic Health Records and Advanced Machine Learning Algorithms*. ArXiv:10.32996/jcsts.2025.7.2.68. [https://www.semanticscholar.org/paper/52398c6bae5d05ce7ea61d7317617252d44eac16](https://www.semanticscholar.org/paper/52398c6bae5d05ce7ea61d7317617252d44eac16)
115. Muhammad Waqar, Muhammad Bilal Shahnawaz, Sajid Saleem, Hassan Dawood, Usman Muhammad, Hussain Dawood (2025). *Enhancing Heart Attack Prediction: Feature Identification from Multiparametric Cardiac Data Using Explainable AI*. ArXiv:10.3390/a18060333. [https://www.semanticscholar.org/paper/0edeb82af75a556a417ee9c571aa3e9f4838745f](https://www.semanticscholar.org/paper/0edeb82af75a556a417ee9c571aa3e9f4838745f)
116. Yuezhou Zhang, A. Folarin, C. Stewart, H. Sankesara, Y. Ranjan, P. Conde, Akash Roy Choudhury, Shaoxiong Sun, Z. Rashid, Richard J. B. Dobson (2025). *An Explainable Anomaly Detection Framework for Monitoring Depression and Anxiety Using Consumer Wearable Devices*. ArXiv:2505.03039. [https://www.semanticscholar.org/paper/37015ba93122de366399a58dc6d48bfb3a5a1962](https://www.semanticscholar.org/paper/37015ba93122de366399a58dc6d48bfb3a5a1962)
117. Antonio Álvarez-López, Marcos Matabuena (2025). *Continuous Temporal Learning of Probability Distributions via Neural ODEs with Applications in Continuous Glucose Monitoring Data*. ArXiv:2505.08698v1. [https://arxiv.org/pdf/2505.08698v1](https://arxiv.org/pdf/2505.08698v1)
118. Yuchen Han, Arnab Ganguly, Riten Mitra (2025). *Nonparametric learning of covariate-based Markov jump processes using RKHS techniques*. ArXiv:2505.03119. [https://www.semanticscholar.org/paper/1ce0fc59a4736fd207ed5b53e15ae78b35ee71a6](https://www.semanticscholar.org/paper/1ce0fc59a4736fd207ed5b53e15ae78b35ee71a6)
119. Min Hyuk Lim, Hyocheol Chae, Jeongwon Yoon, Insik Shin (2025). *A deep learning framework for virtual continuous glucose monitoring and glucose prediction based on life-log data*. ArXiv:10.1038/s41598-025-01367-7. [https://www.semanticscholar.org/paper/c1f1ea9810289b372feb661d21a116a2589e1265](https://www.semanticscholar.org/paper/c1f1ea9810289b372feb661d21a116a2589e1265)
120. Yao-hua Zhang, L. Fresiello, Peter H. Veltink, Dirk Donker, Ying Wang (2025). *Physiological-Model-Based Neural Network for Heart Rate Estimation during Daily Physical Activities*. ArXiv:2506.10144. [https://www.semanticscholar.org/paper/6826dd15ee0d08b5118d29b03203625a0f4c40f0](https://www.semanticscholar.org/paper/6826dd15ee0d08b5118d29b03203625a0f4c40f0)
121. Gulsah Hancerliogullari Koksalmis, Bulent Soykan, Laura J. Brattain, Hsin-Hsiung Huang (2025). *Artificial Intelligence for Personalized Prediction of Alzheimer's Disease Progression: A Survey of Methods, Data Challenges, and Future Directions*. ArXiv:10.48550/arXiv.2504.21189. [https://www.semanticscholar.org/paper/61d78a78cd963df39b0e3408e6f4de3070cd6eaa](https://www.semanticscholar.org/paper/61d78a78cd963df39b0e3408e6f4de3070cd6eaa)
122. Bowen Deng, Chang Xu, Hao Li, Yuhao Huang, Min Hou, Jiang Bian (2025). *TarDiff: Target-Oriented Diffusion Guidance for Synthetic Electronic Health Record Time Series Generation*. ArXiv:10.48550/arXiv.2504.17613. [https://www.semanticscholar.org/paper/63ca8f86de6b2c3299e4fd6fd28e1c24cf040341](https://www.semanticscholar.org/paper/63ca8f86de6b2c3299e4fd6fd28e1c24cf040341)
123. Hongyu Chen, Xiaohan Li, Xing He, Aokun Chen, James McGill, Emily C Webber, Hua Xu, Mei Liu, Jiang Bian (2025). *Enhancing Patient-Trial Matching With Large Language Models: A Scoping Review of Emerging Applications and Approaches*. ArXiv:10.1200/CCI-25-00071. [https://www.semanticscholar.org/paper/cc543eec013f8b3ee878da3d0dc5b11a858960d8](https://www.semanticscholar.org/paper/cc543eec013f8b3ee878da3d0dc5b11a858960d8)
124. Jordi de La Torre (2025). *Scalable Unit Harmonization in Medical Informatics Using Bi-directional Transformers and Bayesian-Optimized BM25 and Sentence Embedding Retrieval*. ArXiv:10.48550/arXiv.2505.00810. [https://www.semanticscholar.org/paper/aa38b9b16c8102688a1d09050ce0eae2e8d0498c](https://www.semanticscholar.org/paper/aa38b9b16c8102688a1d09050ce0eae2e8d0498c)
125. Linus Stuhlmann, Michael Alexander Saxer, Jonathan Furst (2025). *Efficient and Reproducible Biomedical Question Answering using Retrieval Augmented Generation*. ArXiv:2505.07917. [https://www.semanticscholar.org/paper/0f8446ae0441b3f4cd5e5db05d667ad67c572ec2](https://www.semanticscholar.org/paper/0f8446ae0441b3f4cd5e5db05d667ad67c572ec2)
126. Nathan T. Rich, Sarah Salzman, Gabriel Altay, Kunal Nagpal, Vivek Shetye, Gena A Rangel, Poojan Thakkar, Annie Darmofal, Dan Sun, B. O'Neil, A. Zarzour, John Nemunaitis, James F. Maher, Philip E Lammers, Srilata Gundala, T. Pluard, Viran R. Holden, Arpita Saha, Victoria L. Chiou, C. Osterman (2025). *Impact of large language models on trial-to-patient matching efficiency.*. ArXiv:10.1200/jco.2025.43.16_suppl.e13600. [https://www.semanticscholar.org/paper/00bd7358bdce4c2992599451e2d316f25397bab4](https://www.semanticscholar.org/paper/00bd7358bdce4c299259451e2d316f25397bab4)
127. Chao Ding, Mouxiao Bian, Pengcheng Chen, Hongliang Zhang, Tian-Xin Li, Lihao Liu, Jiayuan Chen, Zhuoran Li, Yabei Zhong, Yongqi Liu, Haiqing Huang, Dongming Shan, Junjun He, Jie Xu (2025). *Building a Human-Verified Clinical Reasoning Dataset via a Human LLM Hybrid Pipeline for Trustworthy Medical AI*. ArXiv:2505.06912. [https://www.semanticscholar.org/paper/977586e2442843ba13ee9fe902bd86f7548b56aa](https://www.semanticscholar.org/paper/977586e2442843ba13ee9fe902bd86f7548b56aa)
128. Arturo Loaiza-Bonilla, S. Kurnaz, Ertugrul Tuysuz, Oz Huner, Dersu Giritlioğlu, Juan Pablo Noel Meza (2025). *Transforming oncology clinical trial matching through multi-agent AI and an oncology-specific knowledge graph: A prospective evaluation in 3,800 patients.*. ArXiv:10.1200/jco.2025.43.16_suppl.1554. [https://www.semanticscholar.org/paper/dad80f36a1b8fa757552c76ced3b6e43e093c6c2](https://www.semanticscholar.org/paper/dad80f36a1b8fa757552c76ced3b6e43e093c6c2)
129. Jai Narendra Patel, Michael Cyrus Maher, Robyn Yano, Patrick Jongeneel, Victoria Morris, Wei Sha, Ferdous Ahmed, Melissa Bacchus, Dazhi Liu, Nataya Francis, Pranav Singh, Ognjen Nikolic, Anne-Marie Meyer, Michael Wang, C. Farhangfar, Phil Butera (2025). *Enhancing clinical trial screening with a comprehensive large language model platform.*. ArXiv:10.1200/jco.2025.43.16_suppl.e13674. [https://www.semanticscholar.org/paper/3b7ee1aec6d1fcdc5bc8d3bb3835659bcc1b53db](https://www.semanticscholar.org/paper/3b7ee1aec6d1fcdc5bc8d3bb3835659bcc1b53db)
130. Grace Westerman, Claire T Verhagen, Haley Heaviland, Erin Lynch, Olivia Brandenburg, Jennifer Adams Patton, Regina M. Schwind, Ben George, Anai Kothari (2025). *Enterprise-level AI screening for oncology trials: Improving patient identification with OncoLLM.*. ArXiv:10.1200/jco.2025.43.16_suppl.e13706. [https://www.semanticscholar.org/paper/12f9e0f9e00c38e4fbdbfabad8ecc0a9d178ad3d](https://www.semanticscholar.org/paper/12f9e0f9e00c38e4fbdbfabad8ecc0a9d178ad3d)
131. Yuxing Lu, Gecheng Fu, Wei Wu, Xukai Zhao, Sin Yee Goi, Jinzhuo Wang (2025). *DoctorRAG: Medical RAG Fusing Knowledge with Patient Analogy through Textual Gradients*. ArXiv:2505.19538. [https://www.semanticscholar.org/paper/f185c99b0af3d7598f751ad977b1898ebcd05c33](https://www.semanticscholar.org/paper/f185c99b0af3d7598f751ad977b1898ebcd05c33)
132. Nikita Mehandru, Niloufar Golchini, David Bamman, Travis Zack, Melanie F. Molina, Ahmed Alaa (2025). *ER-REASON: A Benchmark Dataset for LLM-Based Clinical Reasoning in the Emergency Room*. ArXiv:2505.22919. [https://www.semanticscholar.org/paper/55d73c928f98506b438803586382f9a9d8dd98d](https://www.semanticscholar.org/paper/55d73c928f98506b438803586382f9a9d8dd98d)
133. Ran Xu, Yuchen Zhuang, Yishan Zhong, Yue Yu, Xiangru Tang, Hang Wu, M. D. Wang, Peifeng Ruan, Donghan M Yang, Tao Wang, Guanghua Xiao, Carl Yang, Yang Xie, Wenqi Shi (2025). *MedAgentGym: Training LLM Agents for Code-Based Medical Reasoning at Scale*. ArXiv:2506.04405. [https://www.semanticscholar.org/paper/e08574d105b350a5d5a64d4d0cd30316f06bc4f](https://www.semanticscholar.org/paper/e08574d105b350a5d5a64d4d0cd30316f06bc4f)